Review Article

Propolis: A Complex Natural Product with a Plethora of Biological Activities That Can Be Explored for Drug Development

Ricardo Silva-Carvalho,1,2 Fátima Baltazar,1,2 and Cristina Almeida-Aguiar3

1Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710-057 Braga, Portugal
2ICVS/3B’s, PT Government Associate Laboratory, Guimarães, 4710-057 Braga, Portugal
3Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), Biology Department, University of Minho, 4710-057 Braga, Portugal

Correspondence should be addressed to Cristina Almeida-Aguiar; cristina.aguiar@bio.uminho.pt

Received 25 February 2015; Revised 10 May 2015; Accepted 12 May 2015

Academic Editor: Jairo Kennup Bastos

Copyright © 2015 Ricardo Silva-Carvalho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The health industry has always used natural products as a rich, promising, and alternative source of drugs that are used in the health system. Propolis, a natural resinous product known for centuries, is a complex product obtained by honey bees from substances collected from parts of different plants, buds, and exudates in different geographic areas. Propolis has been attracting scientific attention since it has many biological and pharmacological properties, which are related to its chemical composition. Several in vitro and in vivo studies have been performed to characterize and understand the diverse bioactivities of propolis and its isolated compounds, as well as to evaluate and validate its potential. Yet, there is a lack of information concerning clinical effectiveness. The goal of this review is to discuss the potential of propolis for the development of new drugs by presenting published data concerning the chemical composition and the biological properties of this natural compound from different geographic origins.

1. Introduction

Over the years, nature is continually surprising with diversified natural compounds that can be promising sources for the discovery of new drugs important in medicine [1]. In fact, approximately half of the currently available drugs were obtained from natural compounds or related [2]. The use of natural products as an essential route to new pharmaceutical leads is continually growing and is a research field of enormous interest because the different structural range of natural compounds can provide lead compounds for therapeutic improvement based on rationalized molecular modifications [3, 4]. It is well known that scientists have curiosity in herbs and other natural plant products for research; however only in the last years the interest in modified plant products by animals, which normally have been largely ignored and wasted, has been increased [5, 6].

Propolis, a complex mixture of compounds also called bee glue, is a natural resinous product that honeybees collect from several plants and mix it with beeswax and salivary enzymes (β-glucosidase) [7–11]. As inferred for the meaning of the Greek word propolis—pro-, for or in defence, and polis, the city [10]—bees use propolis on their hives as protection against predators and microorganisms, to repair damage, as a thermal isolator, and to build aseptic locals to prevent microbial infection of larvae [7, 9, 10, 12]. Since ancient times, propolis has been used by humans to meet the needs of health and food preservation [5]; but only in the last years the interest in this complex natural product has increased due to its broad spectrum of biological and pharmacological properties [12–14]. Propolis is a lipophilic material that is hard and breakable when cold but soft, flexible, and very sticky when warm; it possesses an enjoyable aromatic smell and different coloration, including brown,
green, and red, among others [5, 7, 12]. In terms of chemical composition, it is generally composed of 50% resin, 30% wax, 10% essential oils, 5% pollen, and 5% other substances which include minerals and organic compounds like phenolic acids (cinnamic and caffeic acid) or their esters, flavonoids (flavones, flavanones, flavonols, and dihydroflavonols chloro-
cones), terpenes, aromatic aldehydes and alcohols, fatty acids, stilbenes, and β-steroids [8, 9]. Analysis of different samples revealed that propolis chemical composition is difficult to standardize because it depends on different phytogeographic characteristics like vegetation, season, and environmental conditions of the site of collection, as bees select different plants in different habitats for propolis production [6, 8, 9]. Several in vitro and in vivo studies have been describing the plethora of biological activities and chemical profiles of propolis from different geographic origins. This review highlights published data about such works focusing on the antimicrobial, anti-inflammatory, antioxidant, immunomodulatory, and antitumor activities of different propolis types, in order to unravel the potential of this natural compound for the development of new drugs.

2. Use of Propolis in Ancient and Current Times

Propolis is not a new discovery. Since bee’s domestication, men explore its products to their own benefit and propolis, one of the most important chemical weapons of bees, is no exception, having been employed extensively since almost immemorial times [6, 13, 15–17]. It is stated that propolis use dates back to ancient times, at least to 300 BC, where it was used in folk medicine and other activities in many parts of the world [16]. It was familiar to the Egyptians, in particular by the priests who controlled medicine and chemistry and knew very well propolis antiputrefactive properties. They learned from the bees the embalming capacity of propolis as this natural product is used to perform the mummification of corpses and prevent spread of infections. The Greek and the Roman physicians also acknowledged the potential of propolis by employing it in wound treatment, as an antiseptic and cicatrizing agent, and as mouth disinfectant. The Persians described propolis as a drug capable of acting against eczemas, myalgia, and rheumatism. Populations of the new world, like Incas, also used propolis as an antipyretic agent.

Between the 17th and 20th century, this natural product became very popular in Europe. In 1969, in the former Union of Soviet Socialist Republics (USSR), the use of propolis was accepted in human and veterinary medicine, with several applications including the treatment of tuberculosis, where the regression of lung problems and recovery of appetite were observed. Also, it was believed to cure some diseases in folk Georgian medicine. During World War II (1939–1945), doctors used propolis to treat wounds [15–17], but only in 1985, in Japan, propolis was considered as very promising in pharmacology. Before that, propolis was considered a product without market value, especially because its production is low and affects honey production. Nowadays, propolis is an important product in alternative medicine in Japan, being widely imported from Brazil [18]. In the 17th century, the Italian Antonio Stradivari who is considered the most significant and the greatest crafter of string instruments, like violins, used propolis as an ingredient in the varnish of his instruments. Curiously, such as in the 17th century, propolis is currently used in rosin for stringed instruments and in the repair of accordions [16].

Propolis is one of the few natural products that maintained popularity for a long time, although it is not considered a therapeutic agent in conventional medicine. Actually, it is widely used as a component in pharmaceutical and cosmetic products such as antiacne creams, facial and body creams, ointments and lotions, and several formulations for oral hygiene [15, 16]. It is also used in some foods and beverages, or simply as food supplement or healthy drinks. This name was attributed to the drinks because it is thought that propolis improves human health and prevents diseases such as heart disease or diabetes, among others [19].

3. Origin and Composition of Propolis

Propolis knowledge has registered an important evolution over time, due to exhaustive studies regarding its chemical composition and biological activities. In the 60s, it was thought that, despite its complexity, propolis chemical composition was more or less constant. Nevertheless, in the following years, analysis of a large number of samples from different geographic origins revealed that chemical composition of propolis is highly variable and also difficult to standardize because it depends on factors such as the vegetation, season, and environmental conditions of the site of collection [6, 8, 9]. Marcucci [7] and Bankova et al. [10] registered more than 300 substances in propolis and recent reports showed the presence of compounds never mentioned before [12, 17, 20, 21].

Generally, the main constituents of propolis are resin and volatiles, which are substances obtained from a variety of botanical processes in different parts of plants, and beeswax, secreted by the bees [9]. Typical compounds are summarized in Table 1. As can be seen, plant sources vary among the different parts of the globe, leading to panoply of compounds. In a review on propolis standardization, different resin types were proposed: poplar propolis, birch, green, red, “Pacific,” and “Canarian” [9, 12]. Samples of poplar propolis (e.g., from Europe, North America, New Zealand, and temperate zones of Asia) are mainly composed of flavonoids, phenolic acids, and their esters [10, 20, 22], clearly different from other propolis types (Table 1). Portuguese propolis, despite similar to the ones found in European samples, also contains new methylated, esterified, and hydroxylated derivatives of flavonoids and pinocembrin/pinobanksin derivatives containing a phenylpropanoic acid derivative moiety in their structure [20, 21]. Our group recently showed that propolis from Pereiro (district of Guarda, Beira Alta) (Figure 1) has a high concentration of phenolic components [23].

Poplar-type propolis is undoubtedly the most studied one but there are many other propolis types. Recent studies have revealed a new type of European propolis: Mediterranean propolis. This type of propolis is distinguished by the high
concentration of diterpenoids and is found in many regions like Greece [24, 25], Switzerland [26], Malta [27], Turkey [28-30], or Algeria [28, 31].

Propolis from tropic regions, like Brazil, Cuba, Venezuela, and Chile, has been attracting much attention in the last years due to its particular chemical profiles. Prenylated phenylpropanoids, prenylated p-coumaric acids, acetophenones, diterpenic acids, and caffeoylquinic acids were shown to be very common and abundant in propolis from Brazil, mainly from the south-eastern region [9, 10, 21]. The flavonoids kaempferide and isosakuranetin and some amounts of kaempferol were also found in Brazilian samples [32]. Additionally, red propolis from the northeast regions of Brazil presents high concentrations of phenolic acids and the flavonoids formononetin, isoliquiritigenin, liquiritigenin, medicarpin, and biochanin A [33–35]. Cuban propolis has a peculiar enrichment in polyisoprenylated benzophenones, more specifically nemorosone, and a minor content of a mixture of xanthochymol and guttiferone E [9, 36] making this type of sample chemically distinct from both European and Brazilian propolis. Propolis from Venezuela is also composed of polyisoprenylated benzophenones in addition to the usual constituents found in samples of tropical regions [9, 37, 38].

Information about the chemical composition of Australian propolis is very limited despite the great biodiversity of the island. Propolis from Kangaroo Island is mainly composed of stilbenes, some of them being prenylated. Additionally, it has also some prenylated cinnamic acids and flavonoids [39], like 2',3',4'-trimethoxychalcone, 2'-hydroxy-3',4'-dimethoxychalcone, 2',4'-dihydroxy-3'-methoxyxchalcone, 5,7-dihydroxy-2,3-dihydroflavonol 3-acetate (pinobanksin 3-acetate), and 5,7-dihydroxy-6-methoxy-2,3-dihydroflavonol 3-acetate [40]. Western Australian propolis is composed of Xanthorrhoeol, pterostilbene, sakuranetin, and pinostrobin [41]. Propolis of Australian stingless bees (Tetragonula carbonaria) is composed of C-methylated flavonanes [42].

"Pacific" propolis (e.g., Okinawa, Taiwan, Hawaii, Indonesia, and Myanmar) is another particular type of propolis. A new family of compounds, the prenyllflavonoids, more specifically isonymphaeol-B, was identified in Okinawa propolis although three already known compounds—nymphaeol-A, nymphaeol-B, and nymphaeol-C—have also been isolated in three samples [43]. As Okinawan propolis, Hawaiian propolis is also composed of nine prenyllflavonoids [44]. Taiwanese propolis is composed of eight prenyllflavonones, nymphaeol-A, nymphaeol-B, and nymphaeol-C, propolins A, B, and E, isonymphaeol B, and 3'-geranyl-naringenin [45]. In another sample of the Pacific region, the Indonesian propolis, an inseparable mixture of four alk(en)ylresorcinols (5-pentadecylresorcinol, 5-(8Z,11Z-heptadecadienyl)-resorcinol, 5- (11Z-heptadeceny)-resorcinol, and 5-heptadecylresorcinol), along with four prenyllflavonones, propolins D, C, F, and G, and three cycloartane-type triterpenes, mangiferolic acid, isomangiferolic acid, and 27-hydroxyisomangiferolic acid, was identified [46]. Additionally, fractioning of propolis extracts from Myanmar led to the isolation of two new cycloartane-type triterpenes, together with 13 cycloartanes and four known prenylated flavanones [47]. Thailand propolis, which might be possibly obtained from Styrax trees, comprises not only the typical compounds of temperate regions but also the two new phenallyflavanones (7'S)-8-[-(4'-hydroxy-3'-methoxyphenyl)prop-2-en-1-yl]-2-(25-pinocembrin and (E)-cinnamyl-(E)-cinnamylidene) [48]. In propolis from Canary Islands, a different phenolic profile was found, fuurofurans lignans being the main compounds. Six fuurofurans lignans were isolated and characterized as sesamin, episesamin, methyl xanthoxylol, amenthin, sesartenin, and yangambin. Propolis also contains sugars and sugar alcohols [10, 49]. Many studies with African propolis from different regions, like Kenya, Cameroon, Congo, Oman, and Ethiopia, showed that triterpenoids are major chemical components [50–53].

Southern Nigeria propolis is uncommon since it presents prenylated isoflavonoids, like Brazilian red propolis, and a high abundance of stilbenoid compounds [54].

Propolis additionally contains minerals such as magnesium, calcium, iodine, potassium, sodium, copper, zinc, manganese, and iron; some vitamins like B1, B2, B6, C, E, and D, as well as provitamin A; a few fatty acids; and also some enzymes derived from bees glandular secretion or possibly from pollen like succinic dehydrogenase, adenosine triphosphatase, glucose-6-phosphatase, acid phosphatase, α-amylase, β-amylase, β-lactamase, β-lactamase, maltase, esterase, and transhydrogenase [17, 55]. Polysaccharides like starch and the di- and monosaccharaides glucose, fructose, ribose, rhamnose, talose, gulose, and saccharose are commonly present in propolis too [55].

4. Biological Properties and Therapeutic Activity of Propolis

Despite propolis popularity over time, it is not considered as a therapeutic agent in conventional medicine as the standardization of chemical composition and biological activity is lacking. Such standardization is indispensable for acceptance in the health system. Thus, characterization of different types of propolis according to its plant origin and corresponding chemical profile is mandatory. Studies about propolis bioactivity must start with chemical profiling of the extracts since that information is essential to have detailed and consistent comparative data between each type
| Geographical origin                                   | Plant source                                           | Typical constituents (main components)                                                                 | References |
|-------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-------------|
| Europe, North America, New Zealand, and temperate     | *Populus* spp., more predominantly *P. nigra*          | Pinocembrin, pinobanksin, chrysin, galangin, caffeic acid, ferulic acid, cinnamic acid, and their esters | [10, 20, 22]|
| zones of Asia                                         |                                                        |                                                                                                       |             |
| Brazil                                                | *Baccharis* spp., predominantly *B. dracunculifolia*   | Prenylated phenylpropanoids, phenolic acids, prenylated *p*-coumaric acids, acetophenones,              | [9, 10, 32, 33]|
|                                                      | *Dulbergia* acastaphyllina                              | diterpenic acids, caffeoylglycinic acids, kaempferide, isosakuranetin, and kaempferol                  |             |
| Russia                                                | *Betula* spp., more specifically *B. verrucosa*, *B. pendula*, and *B. pubescens* | Cinnamic acids, phenylpropanoid sesquiterpenols, acacetin, apigenin, ermanin, rhamnocitrin, kaempferide, α-acetoxybutenol | [10, 180]  |
| Cuba, Venezuela                                       | *Clusia* spp., more specifically *C. rosea* and *C. minor* | Polysoprenylated benzophenones, more specifically neroynosone, xanthochymol, and guttiferone E          | [9, 36]     |
| Mediterranean                                          |                                                        |                                                                                                       |             |
| Greece                                                | Probably *Conifer* spp.                                | Flavonoids, diterpenic acids such as isocupressic, pinaric, and commucic acids, isoagathol,              | [24, 25]    |
|                                                      |                                                        | agathadiol, ferruginol, 8-elemene, and totarol                                                        |             |
| Switzerland                                           | *P. tremula*                                           | Benzyl *p*-coumarate, benzyl ferulate, and phenolic glycerides like dicoumarol acetyl glycerol,        | [26]        |
|                                                      |                                                        | diferuloyl acetyl glycerol, feruloyl coumaroyl acetyl glycerol, and caffeoyl coumaroyl acetyl glycerol  |             |
| Malta                                                 | *Ferula* spp., most probably *Ferula communis*         | Diterpenic acids such as isocupressic, commucic, pinaric, and imbricatolic acid, together with         | [27]        |
|                                                      |                                                        | totarol and 13-epirotulosol                                                                          |             |
| Turkey                                                | *Populus* spp., *Eucalyptus* spp., and *Castanea* sativa | Pinocembrin, pinobanksin and its acetate, prenyl esters of caffeic acid, ferulic acid, diterpenic      | [28–30]     |
|                                                      |                                                        | acids, aromatic esters such as benzyl cinnameate, benzenedicarboxylic acid and flavanols such as       |             |
|                                                      |                                                        | benzyopyran and chrysin                                                                              |             |
| Algeria                                               | *Populus* spp.                                         | Pinocembrin, pinobanksin and its acetate, chrysin, apigenin, pectolinarginen, piloin, ladanein,        | [28, 31]    |
|                                                      |                                                        | galangin, naringenin, techoxychrisin, methoxychrysin, prenylesters of caffeic acid, ferulic acids,     |             |
|                                                      |                                                        | diterpenic acids like hydroxyditerpenic acid, labdane, and clerodane                                 |             |
| Australia                                             | *Acacia* paradoxa                                      | Xanthorrhoeol, pterostilbene, sakuranetin, pinostrobin, stilbenes, prenylated tetrahydroxystilbenes,    | [39–42]     |
|                                                      |                                                        | prenylated cinnamic acids, flavonanes, flavonols, chalcones                                           |             |
| African Stingless bee *Tetragonula carbonaria*        | *Cistus* spp.                                          |                                                                                                       |             |
| Nigeriy                                              | *M. schweinfurthii*                                     | Isoflavonoids, prenylated isoflavonoids, and stilbenoids                                             | [54]        |
| Kenya                                                | *Azadirachta indica*, *Acacia* spp., and *Mangifera* indica | Triterpenes, arylinalphane lignans such as tetrahydrojusticidin B and 6-methoxydiphyllin, geranyl      | [50]        |
| Cameroon                                             | *Stynax* trees                                         | Triterpenes, derivatives of amyrin and lupeol and diprenyl flavonoids                                | [53]        |
| Congo                                                |                                                          |                                                                                                       |             |
| Oman                                                 | *Azadirachta indica*, *Acacia* spp., and *Mangifera* indica | Triterpenes, prenylated flavonones such as 7-O-methyl-8-prenylnaringenin, 3′,8-diprenylnaringeninin,   | [51]        |
|                                                      |                                                        | and 8-prenyl-5,7-dihydroxy-3′-(3-hydroxy-3-methylbutyl)-4′-methoxylflavanone, chalcones, cardanol,      |             |
|                                                      |                                                        | cardols, and anacardic acids                                                                          |             |
| Oman                                                 | *Azadirachta indica*, *Acacia* spp., and *Mangifera* indica | Triterpenoids such as α- and β-amyrans, α- and β-amyril acetates, lupeol, and α- and β-lupeyl         | [52]        |
| Ethiopia                                             | *Acacia* spp.                                          | acetates                                                                                               |             |
| Thailand                                             | *Stynax* trees                                         | Phenylllyflavanone, (E)-cinnamyl-(E)-cinnamylidenate                                                 | [48]        |
| The Pacific region                                    |                                                        |                                                                                                       |             |
| Okinawa, Hawaii, and Taiwan                          | *Macaranga tanarius*                                   | Prenylflavonoids, more specifically isonymphaeol-B, nymphaol-A, nymphaol-B, nymphaol-C, propolins,    | [43–45]     |
|                                                      |                                                        | 3′-geranyl-naringenin                                                                                   |             |
| Indonesia, Myanmar                                   | *Mangifera* indica                                     | Alk(en)lyresorcinols, cycloartane-type triterpenes, cycloartanes, and prenylated flavonones            | [46, 47]    |
| Canary Islands                                        | *Unknown*                                              | Furofuran lignans                                                                                      | [49, 182]   |
of biological activity and chemical data. This information allows extrapolating the possible activity and mechanism of action of new propolis under study and provides substantial clues for the development of new drug candidates [6, 9].

In the last decades, several studies have demonstrated the biological and pharmacological actions of different worldwide propolis samples. The following sections summarize the recent published information about antibacterial and antifungal [6, 7, 56–59], antiviral [7, 59, 60], anti-inflammatory [61], antioxidant [62–64], immunomodulatory [6, 65, 66], and antitumor activities [8, 17, 23, 64, 66, 67], revealing the interest of researchers in this bee product and its potential for the development of new drugs as well.

4.1. Antioxidant Activity. It is well known that an endogenous stimuli, like cellular metabolism, and exogenous agents like UV, toxins, and drugs, among others, generate reactive stimuli, like cellular metabolism, and exogenous agents like metal ions, mainly iron and copper, that are involved in the reactions that lead to the lipid peroxidation; by chelating other biomolecules, when exposed to the reactive species, suffer oxidative modifications that modify the cell and lead to its death [68–70]. Oxidative stress is responsible for the occurrence of a wide variety of human diseases, such as neurodegenerative [71] or cardiovascular diseases [72, 73], cancer [68, 74], diabetes [6], and atherosclerosis [75].

In the last years, several studies have been performed to evaluate the antioxidant capacity of natural products. Propolis extracts, composed of different polyphenols, have been reported to possess a potent antioxidant activity [70, 76, 77]. Additionally, the chemical varieties in different propolis samples from different regions have an influence on the antioxidant activity. Recently, Fabris et al. showed that a sample of Italian and Russian propolis ethanol extract (PEE), which have a similar polyphenolic composition, have a similar antioxidant activity, while Brazilian PEE, which have low polyphenolic composition, have a weak antioxidant activity [78]. Another study also showed, using different samples of Transylvania PEE, a positive correlation between high polyphenolic composition and high antioxidant activity [79]. Phenolic acids and flavonoids are characterized by a powerful antioxidant activity, which is closely related to the chemical structure of the compounds [80]. Briefly, the antioxidant activity is exerted by inhibiting the activity of some enzymes (e.g., xanthine oxidase, protein kinase C, ascorbic acid oxidase, cyclooxygenase, lipoygenase, Na+/K+ATPase, and cAMP phosphodiesterase) which inhibit the production of ROS species; by scavenging, interrupting the reactions that lead to the lipid peroxidation; by chelating metal ions, mainly iron and copper, that are involved in the process of free radical creation; or by potentiating the action of other antioxidants [55]. Table 2 summarizes some of the studies addressing the antioxidant activity of propolis.

Moreira et al. [62] and Miguel et al. [63] proposed that Portuguese propolis, an important source of total phenols, flavones, and flavonoids, could be beneficial for human health due to its antioxidant properties. Portuguese propolis also protects human erythrocytes from free radicals damaging by decreasing lipid peroxidation [64]. These studies suggest that Portuguese propolis is a powerful antioxidant agent that can be used against oxidative stress, thus maintaining the structural and functional integrity of the cells. Cuesta-Rubio et al. [36] demonstrated that nemorosone, the most abundant polyisoprenylated benzophenone present in Cuban propolis, exhibits antioxidant capacity. However, when this compound suffers methylation, a process that facilitates the separation of the compound from the propolis sample, the antioxidant property is abolished. Ethyl acetate extract of Kangaroo Island propolis, which is rich in stilbenes, showed a stronger scavenging activity [39]. Yang et al. showed that ethyl acetate of propolis collected in Anhui, China, has strong scavenging activity and ferric reducing activity, those activities being influenced by caffeic acid, phenethyl caffeate, cinnamyl caffeate, and benzyl caffeate [81]. Another study showed that samples of methanolic extracts of Algerian propolis that contains high amounts of caffeic acid esters and flavanones, kaempferol, and galangin possess strong scavenging activity and ferric reducing activity [31]. Uruguay propolis with high polyphenolic composition inhibits low-density lipoprotein (LDL) peroxidation and protein nitration in vitro. Moreover, it induces the expression of nitric oxide synthase (eNOS) and inhibits NADPH oxidase in bovine aortic endothelial cells [82]. In another study, the topical administration of Romanian PEE in mouse, either prior to or after UVB exposure, significantly attenuated the malondialdehyde (MDA) formation and restored glutathione peroxidase (GSH-Px) activity [83]. Talas et al. [84] showed that Turkish PEE has antioxidant properties in the liver tissue of NOS inhibited rats. In fact, NOS inhibition caused an increase in CAT activity and MDA levels, effect that was significantly decreased when the rats were treated with PEE. It is well known that propolis composition is variable; nevertheless, one of its major components, CAPE (caffeic acid phenethyl ester), plays an important role in the antioxidant activity [85–87].

Antioxidant activity is one of the most studied and important activities of propolis, though there are no studies with data on the safe dose to be used in humans. Thus, clinical studies using propolis and its active compounds are needed.

4.2. Anti-Inflammatory Activity. Inflammation is an event that normally occurs in response to the constant exposure to environmental and endogenous stimuli as well as to accidental damage [61]. A complex cascade of chemical signals initiates after tissue injury and maintains a host response to repair the injured tissue. There are two stages of inflammation: acute and chronic. Acute inflammation is mediated through the activation of the immune system cells, which migrate to the site of damage and release growth factors, cytokines, and ROS/RNS species. Chronic inflammation occurs when the acute inflammation is not successfully resolved. This inflammatory condition plays a critical role in the pathogenesis of many diseases including atherosclerosis, cancer, asthma, Alzheimer’s, and Parkinsonism [88, 89].

Several studies have associated different types of propolis and its various constituents with anti-inflammatory activity [61, 90–95]. Table 3 summarizes the anti-inflammatory
| Origin                                      | Propolis type/plant source | Type of extract/isolated compound(s) | Species/cells            | Effect                                                                 | References |
|--------------------------------------------|---------------------------|-------------------------------------|--------------------------|------------------------------------------------------------------------|------------|
| Portugal (Serra de Bpanes and Fundao)     | European propolis/Populus nigra | Methanolic extract                  | Human erythrocytes       | Decrease in lipid peroxidation                                         | [64]; [62] |
| Brazil                                     | Propolis from the stingless bee *Melipona orbignyi* or probably popular tree | PEE                              | Human erythrocytes       | Free radical scavenging; inhibition of hemolysis and lipid peroxidation | [183]      |
| Portugal (Central Algarve)                 | European propolis/Populus nigra | PEE and methanolic extracts          | Free radical scavenging, metal ions     | [63]                                                                   |            |
| Cuba                                       | Red propolis/C. rosea     | Methanolic extract and Nemorosone   | Free radical scavenging   | [36]                                                                   |            |
| Slovenia                                   | European propolis/Populus nigra | PEE                              | Female Swiss mice (UV exposure) | Decrease in malondialdehyde levels, restoration of glutathione peroxidase activity | [83]       |
| Romania                                    | Australian propolis/ *Acacia para doxa* | Ethyl acetate extract; stilbene     | Free radical scavenging   | [39]                                                                   |            |
| China                                      | European propolis/Populus nigra | Ethyl acetate extract               | Free radical scavenging and ferric reducing activity | [81]                                                                |            |
| Algeria                                    | Mediterranean propolis/Populus spp. and Cistus spp. | Methanolic extract                 | Free radical scavenging and ferric reducing activity | [31]                                                                |            |
| Uruguay                                    | European and green propolis/Populus nigra and B. dracunculifolia | PEE                              | Bovine aortic endothelial cells | Inhibition of low-density lipoprotein peroxidation and NADPH oxidase and increase in nitric oxide synthase | [82]       |
| Brazil                                     | Green propolis/B. dracunculifolia | PEE                              | C57BL/6 mice (acute lung inflammation caused by cigarette smoke) | Normalization of nitrite, myeloperoxidase levels, superoxide dismutase, catalase, and glutathione peroxidase activity and reduction of glutathione/oxidized glutathione ratio and malondialdehyde levels | [185]      |
| Turkey                                     | Mediterranean propolis/Populus spp., Eucalyptus spp., and Castanea sativa | PEE                              | Fibroblast cells; Male Wistar rats; Carps (Cyprinus carpio) | Decrease of DNA damage induced by H2O2; Decrease in CAT activity and MDA levels in NOS inhibited rats; Decrease in malondialdehyde levels, superoxide dismutase activity and increase of catalase and glutathione peroxidase activity | [186]; [84]; [187] |
| Purchased from Sigma Aldrich Co.           | Characteristic of European type propolis | CAPE                          | Male Wistar albino rats, Peripheral blood mononuclear cells from cyclists | Free radical scavenging, inhibition of xanthine oxidase activity and lipid peroxidation; Maintenance of superoxide dismutase activity, decrease of xanthine oxidase activity and malondialdehyde and nitric oxide levels; Reduction of hyperthermia-induced survival inhibition, necrosis, superoxide production, glutathione depletion, and intracellular superoxide | [85]; [86]; [87] |
| Origin          | Propolis type/plant source | Type of extract/isolated compound(s) | Species/cells                          | Effect                                                                 | References |
|-----------------|---------------------------|--------------------------------------|----------------------------------------|------------------------------------------------------------------------|------------|
| Purchased: Sigma Aldrich Co. Synthesized | Characteristic of European, Brazilian, and Mediterranean propolis | Caffeic acid, quercetin, naringenin; CAPE | Peritoneal macrophages | Suppression of lipoxygenase pathway of arachidonic acid metabolism CAPE being the most potent modulator of the arachidonic acid cascade | [90]       |
| Croatia         | European propolis/Populus nigra | Water-soluble derivatives PEE | Swiss albino mice Male Swiss albino mice | Reduction of DNA damage in peripheral lymphocytes Suppression of functional activity of macrophages | [188] [104] |
| Purchased: Sigma Aldrich Co. | Characteristic of European type propolis | CAPE | J774 macrophages, Male Wistar rats Male Wistar albino rats Gastric epithelial cell line (AGS), *H. pylori* (strain NCTC 11638) | *In vitro* and *in vivo* inhibition of cyclooxygenase 1 and cyclooxygenase 2 activity Decrease of polymorphonuclear neutrophil leukocyte infiltration in the lungs tissues Inhibition of *H. pylori*-induced NF-κB and activator protein 1-DNA-binding activity; prevention of IkBα degradation in AGS; and suppression of TNF-α and interleukin 8 production Decrease of cyclooxygenase 2 expression, NF-κB activity, c-Jun-N-terminal kinase, inhibitor of NF-κB kinase (IKK), and inhibitor of NF-κB (IkB) phosphorylation | [91, 189] [190] [191] |
| Purchased: Wako Pure Chemical Industries, Ltd. | Brazil Green propolis/B. dracunculifolia | PEE | RAW 26.47 macrophages Male Swiss inbred strain mice | Downregulation of NF-κB, p38 mitogen-activated protein kinase, and c-Jun-N-terminal kinase | [101] |
| Brazil          | Green propolis/B. dracunculifolia | PEE | Sprague-Dawley rats | Inhibition of carrageenan-induced rat hind paws edema and the chemotaxis of human polymorphonuclear leukocytes (PMNs) | [95]       |
| Synthesized     | Characteristic of European type propolis | CAPE | Polymorphonuclear leukocytes obtained from Human blood | Inhibition of 5-lipoxygenase activity and arachidonic acid release | [103] |
| Chile           | European propolis/poplar trees | PEE | Male CF-1 mice | Inhibition of NO release by the macrophages | [102] |
| China           | European propolis/Populus nigra | PEE and PWE | Male ICR mice and male Wistar rats | Inhibition of the activation and differentiation of mononuclear macrophages; decrease prostaglandin-E2 (PGE2) and nitric oxide (NO) levels | [61]       |
| Brazil          | Green propolis/B. dracunculifolia | PWE | Swiss and BALB/c mice | Decrease in the number of macrophages and neutrophils; inhibition of proinflammatory cytokines and increase of anti-inflammatory cytokines Decrease in renal macrophage infiltration in rats with chronic kidney disease | [99] [100] |
| Nepal           | Nepalese propolis/probably Shorea robusta, Dalbergia sissoo, Acacia catechu, and Bombax cieba | PEE, 3',4'-dihydroxy-4'-methoxydalbergione, 4'-ethoxydalbergion, ceartin, and chrysin | Bone marrow-derived mast cells (BMMC) from C57Bl/6 mice | Inhibiting IL-6, TNF-α, and IL-13 gene expression in BMMC and also inhibiting the activation of IKK leading to NF-κB inactivation | [96]       |
mechanisms investigated with propolis and its chemical constituents. Recently, the role of the flavonoids quercetin, flavonols, and flavones in modulating inflammatory cell function was studied [92]. Funakoshi-Tago et al. [96] investigated the anti-inflammatory effects of flavonoids isolated from Nepalese PEE on the IL-33 signaling pathway. The isolated flavonoids 3′,4′-dihydroxy-4-methoxydalbergione, 4-methoxydalbergion, cearion, and crenin inhibited the expression of inflammatory genes including IL-6, TNF-α, and IL-13 in bone marrow-derived mast cells (BMMCs) and also inhibited the activation of IKK, which leads to the degradation of IkBα and inhibits the activation of nuclear factor κB (NF-κB).

The release and oxygenation of arachidonic acid are a critical event in inflammation. Mirzoeva and Calder [90] demonstrated that propolis components such as CAPE, caffeic acid, quercetin, and naringenin, among others, inhibit the production of eicosanoids. In fact, these components significantly suppressed the lipoxygenase pathway of arachidonic acid metabolism, CAPE being the most potent modulator. Another study indicated that CAPE treatment improves hepatic steatosis induced by high-fat diet in a mouse model. This effect was attributed to the reduction of c-Jun-N-terminal kinase ([JNK]2/2) and NF-κB activation with decrease in COX-2 expression [97]. Recently, it was reported that CAPE exhibits inhibitory effects on the production of proinflammatory cytokines (interleukin-1β (IL-1β)), tumor necrosis factor-α (TNF-α), and monocyte chemoattractant protein 1 (MCP-1) from lipopolysaccharide- (LPS-) stimulated RAW264.7 macrophages [98]. Machado et al. [99] showed that Brazilian green propolis water extracts (PWE) modulate an anti-inflammatory cellular response in the model of LPS-induced pulmonary inflammation by decreasing the number of macrophages and neutrophils. Additionally, it induced a reduction in the secretion of IL-6 and TNF-α and an increase in TGF-β and IL-10. Another study showed that Brazilian red PEE promotes a significant decrease in renal macrophage infiltration in rats with chronic kidney disease [100]. Búfalo et al. [101] demonstrated that Brazilian PEE and caffeic acid inhibited LPS-induced NO production by RAW264.7 macrophages, acting at the transcriptional level and suggesting that their anti-inflammatory effects were mediated by downregulating NF-κB, p38 MAP kinase, and JNK1/2. According to Naito et al. [93], topical application of Brazilian PEE is effective in inhibiting carriagean-induced hind paw edema. This sample appears to inhibit the chemotaxis of human polymorphonuclear leukocytes (PMNs), which also contributes to its anti-inflammatory effects. Another study showed the topical anti-inflammatory activity of propolis from Chile in mice ear with induced-edema. In fact, PEE from Buin, Chile, was the most active against the inflammation induced by 12-O-tetradeca-noylphorbol-13-acetate and arachidonic acid and also inhibits significantly NO release by the macrophages [102]. More recently, Boudreau et al. [103] indicated that CAPE is a potent leukotriene biosynthesis inhibitor in PMNs that blocks 5-lipoxygenase (5-LO) activity and arachidonic acid release. A Croatian PEE may improve psoriatic-like skin lesions, which were induced in the study by irritant agents like n-hexyl salicylate or di-n-propyl disulfide, by reducing the lipid peroxidation in the skin and total number of inflammatory cells in the skin and peritoneal cavity, more specially by suppressing functional activity of macrophages [104].

### 4.3. Immunomodulatory Activity

Natural substances are considered alternative adjuvant therapies in the treatment of different diseases due to their immunomodulatory effects. Information about this type of activity was scarce for propolis until the 1990s; but published work in the last years has provided information about the influence of different propolis samples on the immune system [65, 105–112] (Table 4).

In a study using Brazilian green propolis, it was seen that the administration for 3 days of a PEE to male BALB/c mice modulated the activation of the initial steps of the immune response by upregulating toll-like receptor-2 (TLR-2) and toll-like receptor-4 expression and proinflammatory cytokines (IL-1 and IL-6) production by macrophages and spleen cells [105]. Another study demonstrated that Brazilian green PEE upregulates TLR-4 and CD80 expression in human monocytes as well as TNF-α and IL-10 production [113]. It was also shown that caffeic acid stimulates the activity of monocytes against C. albicans but it inhibits TLR-2 and HLA-DR expression as well as TNF-α and IL-10 production [114].

Additionally, Missima et al. [115] showed that Brazilian green PEE administered to stressed mice reduces the proinflammatory cytokines IL-1β and IL-6. When administered to melanoma-bearing mice submitted or not to chronic stress, it induces high levels of IL-1β and IL-6 and also stimulates Th1 cytokines production, indicating the activation of antitumour cell-mediated immunity. Bachiega et al. [116] investigated the immunomodulatory effect of propolis and cinnamic and coumaric acids on cytokines IL-1β, IL-6, and IL-10 production. Peritoneal macrophages from BALB/c mice were incubated with different concentrations of propolis (5, 50, and 100 mg/well) and coumaric and cinnamic acids (50 and 100 mg/well). Propolis and the acids stimulated IL-10 production, whereas propolis inhibited LPS effects both before and after its addition. Additionally, propolis and cinnamic and coumaric acids inhibited IL-10 production. A study which evaluated the effect of Brazilian green propolis on macrophage activation by H₂O₂ and NO metabolite determination [107] showed that propolis increased H₂O₂ generation and decreased NO generation, which favours the microbicidal activity. Recently, the immunomodulatory effect of propolis collected in Brazil was evaluated in Leishmania (Vainiannia) braziliensis experimental infection. Data shows that macrophages incubated with propolis showed a significant increase in interiorization and further killing of parasites. Also, an increased TNF-α production was seen in propolis-pretreated mice, whereas IL-12 was downregulated during the infection [117].

The immunomodulatory action of propolis does not occur only at the macrophage level. In fact, some studies show that this action has also an effect on lymphocyte proliferation [106, 108]. Sá-Nunes et al. [108] showed inhibitory
| Origin | Propolis type/plant source | Type of extract/isolated compound(s) | Species/cells | Effect | References |
|--------|---------------------------|-------------------------------------|--------------|--------|------------|
| Brazil | Green propolis/B. dracunculifolia | PEE, cinnamic and coumaric acids | Male BALB/c mice | Upregulation of toll-like receptor-2 and receptor-4 expression and increases in interleukin-1 and interleukin-6 production | [105] |
|         |                           |                                     | Male C57BL/6 mice, B6F10 cell line | Stimulation of the expression and production of interleukin-2 and interleukin-10 and Th1 cytokine (interleukin-2 and IFN-γ) production | [111] |
|         |                           |                                     | Male BALB/c mice | Inhibition of Th1 cells generation; reduction of the frequency of IFN-γ-producing CD4+ T cells under Th1-polarizing conditions | [192] |
|         |                           |                                     | Male BALB/c mice | Increase of H2O2 generation and decreases in the NO generation in peritoneal macrophages | [109] |
|         |                           |                                     | Male BALB/c mice | Increase in the interiorization and killing of the parasites Leishmania (Yamuis) braziliensis by macrophages; increase in TNF-α production and decrease in interleukin-12 production | [117] |
|         |                           |                                     | Male BALB/c mice | Upregulation of toll-like receptor-2 and receptor-4 mRNA expression | [118] |
|         |                           |                                     | Male BALB/c mice | Stimulation of interleukin-2 and interleukin-10 and Th1 cytokine (interleukin-2 and IFN-γ) production | [192] |
| Brazil | Green propolis/B. dracunculifolia | Hydroalcoholic (HPE) solution | Male BALB/c mice | Increase of H2O2 generation and decrease of NO generation | [107] |
|         |                           |                                     | Male BALB/c mice | Decrease of splenocyte proliferation and increase of IFN-γ production | [108] |
| Indonesia | The Pacific region propolis/Macaranga tanarius and M.Indica | HPE | Male BALB/c mice | Increase of IgG generation and macrophage phagocytosis activity and capacity | [110] |
| Turkey | Mediterranean propolis/Populus spp., Eucalyptus spp., and Castanea sativa | PEE | Peripheral blood mononuclear cells from healthy humans | Suppression of neopterin release and tryptophan degradation, downregulation of the enzyme indoleamine 2,3-dioxygenase (IDO) and decrease of IFN-γ and TNF-α levels | [194] |
|         |                           |                                     | Human monocyte-derived dendritic cells (MoDCs) generated from peripheral monocytes | Inhibition of IL-12 p40, IL-12 p70, IL-10, IFN-γ-inducible protein-10 levels; inhibition of IkBα phosphorylation and NF-κB activation | [112] |
|         |                           |                                     | Female BALB/c mice | Increase of IgM antibody production, T lymphocyte proliferation, interleukin-4 and interleukin-2 production by splenocytes, and IFN-γ production | [195] |
|         |                           |                                     | Human peripheral blood mononuclear cells, Jurkat cells | Inhibition of transcription factors NF-κB and NFAT; inhibition of interleukin-2 gene transcription, interleukin-2 receptor expression, and proliferation of human T cells | [94] |
effects of Brazilian green propolis on splenocyte proliferation, effect that was attributed to flavonoids, and enhancement effects on interferon-γ (IFN-γ) production by spleen cells. CAPE displays inhibitory effects on transcription factors NF-κB and NFAT and, as a consequence, inhibits IL-2 gene transcription, IL-2 receptor expression, and proliferation of human T cells [94]. This provides new information into the molecular mechanisms involved in the anti-inflammatory and immunomodulatory activities of propolis. CAPE has various biological activities but its effect on the immunomodulatory activity remains little studied. According to Wang et al. [112], CAPE can be useful in the treatment of asthma and other allergic diseases because it can inhibit cytokines and chemokines production by human monocyte-derived dendritic cells (MoDCs), which might be related to the NF-κB signalling pathway. Another study demonstrated for the first time that Brazilian propolis significantly inhibited the generation of Th1 cells. Furthermore, the effects of propolis were investigated on 2,4,6-trinitrobenzene sulfonic acid- (TNBS-) induced colitis in a mouse model. Propolis reduced the frequency of IFN-γ-producing CD4+ T cells in a dose-dependent way under Th1-polarizing conditions. The inhibitory effect of propolis on Th1 differentiation was demonstrated in vivo too, and the severity of colitis in propolis-fed mice was significantly lower than that of mice fed with the control diet [118].

4.4. Antiviral Activity. Propolis comprises a complexity of compounds which play a role in antiviral protection. Despite the few data available regarding this activity, it was shown that propolis from different geographic regions has considerable antiviral activity by acting at different levels and interfering with the replication of some viruses [12], like herpes simplex types 1 and 2, adenovirus type 2, influenza virus, or human immunodeficiency virus (HIV), among others [7, 60, 119–124]. Table 5 summarises the antiviral activity of propolis and its chemical constituents.

Schnitzler et al. [123] analysed the antiviral effect of PWE and PEE from Czech Republic as well as that of the constituents caffeic acid, p-coumaric acid, benzoic acid, galangin, pinocembrin, and chrysin, against herpes simplex virus type 1 (HSV-1) in cell culture. Both extracts exhibited high anti-HSV-1 activity when cells were treated prior to viral infection, galangin and chrysin being the main bioactive compounds. Amoros et al. [60] showed the antiviral activity of the major flavonoids of propolis, more specifically flavonols and flavones, the first being more active against HSV-1. Additionally, they analysed the effect of propolis on several DNA and RNA viruses (HSV-1, HSV-2, adenovirus type 2, vesicular stomatitis virus (VSV), and poliovirus type 2). Propolis at a concentration of 30 µg/mL reduced the titer of herpes virus; however, vesicular stomatitis virus and adenovirus were less susceptible. In addition, propolis appears to exert a virucidal action on the enveloped viruses HSV and VSV [120]. Recently, it was shown that hydromethanolic extract of geopropolis from the stingless bee Scaptotrigona postica (Brazil) inhibits the HSV replication and also the entry of the virus into cells, effect that was attributed to the C-glycosyl flavones, catechin-3-O-gallate, and 3,4-dicaffeoylquinic acid [125]. According to Tait et al. [126], natural and synthetic flavonoids might interfere with picornavirus replication preventing the decapsidation of viral particles and RNA release within cells or blocking viral RNA synthesis. These authors also showed that different homoisoflavonoids have good antiviral activity against the coxsackie viruses B3, B4, and A9 and echovirus 30. Shvarzbeyn and Huleihel [127] tried to determine which step of Tax oncprotein-induced NF-κB activation is blocked by propolis and CAPE and showed that both substantially inhibited the activation of NF-κB-dependent promoter by Tax. Also, they strongly prevented both Tax binding to IkBα and its induced degradation by Tax. Ma et al. [128] showed that nanometer propolis flavones could significantly inhibit in vitro porcine parvovirus (PPV) infecting PK-15 cells and in vivo they restrain the PPV copy in lung, gonad, and blood, decrease the impact of PPV on weight of guinea pigs, and increase hemagglutination inhibition of PPV in serum as well as improving the contents of IL-2, IL-6, and γ-IFN.

Over recent years, therapeutic benefits of propolis and/or its isolated compounds have been described in HIV treatment. Ito et al. [129] tested the anti-HIV activity in H9 lymphocytes of triterpenoids melliferone, moronic acid, anuweizonic acid, and betulonic acid and four known aromatic compounds isolated from Brazilian propolis and showed that moronic acid had significant anti-HIV activity. Gekker et al. [119] assessed the anti-HIV-1 activity of propolis in CD4+ lymphocytes and microglial cell cultures, observing the inhibition of viral expression in a concentration-dependent way. The possible mechanism of propolis antiviral property was suggested to involve inhibition of viral entry.

4.5. Antimicrobial Activity. Antimicrobial activity, one of the most studied propolis biological properties, is very well documented. This bioactivity has been largely investigated in the last years due to the need of new treatments against infectious diseases, especially with the increase of resistant pathogens to current antibiotics. Tables 6 and 7 summarise the antibacterial and antifungal activities found in propolis from different geographic origin and/or its chemical constituents.

4.5.1. Antibacterial Activity. Propolis effect against several bacterial strains has evaluated [7, 56–59, 130] and supported the fact that propolis is more active against Gram-positive bacteria than Gram-negative bacteria [12, 59]. Briefly, data from different studies showed that propolis inhibits bacterial motility and enzyme activity, exhibits bacteriostatic activity against different bacterial genera, can be bactericidal in high concentrations, and affects cytoplasmic membrane [130].

Mirzoeva et al. [130] investigated the effect of PEE on the physiology of Bacillus subtilis, Escherichia coli, and Rhodobacter sphaeroides, proposing that propolis and some of its components, like cinnamic acid and flavonoids, affect the ion permeability of the inner bacterial membrane causing the dissipation of the membrane potential and inhibiting bacterial motility. A recent study [131] provided valuable information for understanding the potential anti-H. pylori
Table 5: Antiviral activity of propolis and its chemical constituents.

| Type of extract/extracellular compound(s) | Source of Propolis | Species/cells/viruses | Effect | References |
|------------------------------------------|-------------------|-----------------------|--------|------------|
| Caffeic acid, p-coumaric acid, benzoic acid, galangin, pinocembrin, and chrysin | Characteristic of European type propolis | RC-37 cells, herpes simplex virus type 1 (HSV-1), and A549 | Reduction of herpes simplex virus type 1 (HSV-1) replication in vitro | [123] |
| 3,4-dicaffeoylquinic acid | Characteristic of Brazilian propolis | RC-37 cells, herpes simplex virus type 2 (HSV-2), and A549 | Reduction of herpes simplex virus type 2 (HSV-2) replication in vitro | [124] |
| Homoisoflavonoids, specially 3-benzyl-4-chromones | Characteristic of Brazilian red and green propolis | BGM (Buffalo Green Monkey) cells, coxsackieviruses B3, B4, and A9, and echovirus 30 | Good antiviral activity against the coxsackieviruses B3, B4, and A9 and echovirus 30 | [125] |
| Moronic acid | Characteristic of Brazilian green propolis | PPE | Moronic acid inhibiting anti-HIV replication | [126] |
| | Characteristic of Brazilian green propolis | Capnocytophaga ochracea | Inhibition of C. ochracea growth in vitro | [127] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of A549 cell viability | [128] |
| | Characteristic of Brazilian red and green propolis | Jurkat, uninfected human T-cell lines, and MT2 (HTLV-1 infected human T cells) | Inhibition of HIV replication | [129] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [130] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [131] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [132] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [133] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [134] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [135] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [136] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [137] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [138] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [139] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [140] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [141] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [142] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [143] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [144] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [145] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [146] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [147] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [148] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [149] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [150] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [151] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [152] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [153] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [154] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [155] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [156] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [157] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [158] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [159] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [160] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [161] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [162] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [163] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [164] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [165] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [166] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [167] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [168] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [169] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [170] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [171] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [172] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [173] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [174] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [175] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [176] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [177] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [178] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [179] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [180] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [181] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [182] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [183] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [184] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [185] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [186] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [187] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [188] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [189] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [190] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [191] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [192] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [193] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [194] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [195] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [196] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [197] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [198] |
| | Characteristic of Brazilian red and green propolis | A549 | Reduction of HIV replication | [199] |
Table 6: Antibacterial activity of propolis and its chemical constituents.

| Origin                  | Propolis type/plant source                  | Type of extract/isolated compound(s) | Species                                                                 | Effect                                                                                      | References |
|-------------------------|--------------------------------------------|--------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------|
| Purchased: Bee Health Ltd. (Scarborough, Yorkshire, UK); Purchased: Sigma Chemical Co. (Poole, Dorset, UK) | European propolis/Populus nigra | PEE                                   | B. subtilis SG38, E. coli, and R. sphaeroides                          | Influencing the ion permeability of the inner bacterial membrane; Inhibition of bacterial motility | [130]      |
| Greece                  | Mediterranean propolis/probably Conifer spp. | Terpenes (isolated from Cretan propolis) | S. aureus (ATCC 25923), S. epidermidis (ATCC 12228), E. coli (ATCC 25922), E. cloacae (ATCC3547), K. pneumoniae (ATCC 13883), and P. aeruginosa (ATCC 227853) | Influencing the Gram-positive and Gram-negative bacteria viability                           | [199]      |
| France                  | European propolis/Populus nigra            | Dichloromethane extract              | Gram-negative: 7 Acinetobacter baumannii (BCH, SAN008, 12, AYE, CIP004, 107292, and 5377), 2 Escherichia coli (ATCC 25922 and a clinical isolate), 3 Pseudomonas aeruginosa (ATCC 27853 and two clinical isolates), and 4 clinical isolates of Enterobacter cloacae, E. aerogenes, Klebsiella oxytoca, and Salmonella enteritidis (phage type 4) Gram-negative: 13 Staphylococcus aureus (ATCC 25923, six methicillin-susceptible clinical isolates, and six methicillin-resistant clinical isolates), 2 clinical isolates of S. epidermidis (methicillin-resistant), 3 clinical isolates of Enterococcus faecalis and 1 E. faecium, and 1 clinical isolate of Corynebacterium striatum | Influencing the Gram-positive bacteria viability specially S. aureus and several of its methicillin-resistant and methicillin-susceptible | [133]      |
| Bulgaria                | Mediterranean propolis                      |                                      |                           |                                                                                           |            |
| Greece                  | Mediterranean propolis                      |                                      |                           |                                                                                           |            |
| Turkey                  | Mediterranean propolis                      |                                      |                           |                                                                                           |            |
| Algeria                 | Mediterranean propolis                      |                                      |                           |                                                                                           |            |
| Australia               | Australian propolis from stingless bee      |                                      |                           |                                                                                           |            |
| Cameroon and Congo      | African propolis/probably M. schwemfurthii  |                                      |                           |                                                                                           |            |
| Brazil                  | Green propolis/B. dracunculifolia           |                                      |                           |                                                                                           |            |
| Czech Republic          | European propolis/Populus nigra            | Dimethylsulfoxide extract            |                           |                                                                                           |            |
| Italy                   | Mediterranean propolis/Compressus spp       |                                      |                           |                                                                                           |            |
| Brazil                  | Red propolis/D. eastphylillum; Green propolis/B. dracunculifolia |                                      |                           |                                                                                           |            |
### Table 6: Continued.

| Origin     | Propolis type/plant source                                                                 | Type of extract/isolated compound(s) | Species                                                                 | Effect                                                                                                                                                                                                 | References |
|------------|-------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Poland     | European propolis/Populus nigra and some species of Betula alba, Alnus glutinosa, Aesculus hippocastanum, Fagus sylvatica | Coagulase-positive *S. aureus* strains isolated from blood clinical samples, *S. aureus* (ATCC 25923), *S. aureus* (ATCC 43300), methicillin-sensitive and resistant *S. aureus* | Inhibition of *S. aureus* growth and bactericidal activity; potentiation of antistaphylococcal drugs action; effective against twelve *S. aureus* strains, with MIC values within 0.39 to 0.78 mg/mL and MBC within 0.78 to 3.13 mg/mL | [132]       |
| Brazil;    | Green propolis/B. dracunculifolia;                                                        | PEE                                 | *S. typhi* (00238)                                                      | Brazilian propolis having bacteriostatic activity; Bulgarian propolis having bactericidal activity; both having similar synergetic effect when in combination with amoxicillin, ampicillin, and cephalixin | [202]      |
| Bulgaria   | Mediterranean propolis/Populus spp.;                                                      | PEE                                 | *S. typhimurium*                                                       | Increase of bactericidal activity of macrophages                                                                                                                                                    | [203]      |
| Turkey     | Mediterranean propolis/Populus spp., Eucalyptus spp. and Castanea sativa                  | PWE                                 | *M. tuberculosis* (H$_3$R$_r$), male guinea-pig                        | Inhibition of tuberculous infection in guinea-pigs since it promotes a decrease in necrosis formation and increase in granuloma formation                                                                 | [204]      |
| Turkey     | Mediterranean propolis/Populus spp., Eucalyptus spp. and Castanea sativa                  | PEE                                 | *E. coli* (ATCC 35218), *K. pneumonia* (ATCC 27736), *P. aeruginosa* (ATCC 27853), Morganella morgani (clinical isolate), *S. aureus* (ATCC 25923), *B. subtilis* (ATCC 6633), and *Proteus vulgaris* | Inhibition of Gram-negative bacteria growth                                                                                                                                                            | [134]      |
| Purchased from Sigma Aldrich Co. | Characteristic of European propolis                                                      | CAPE                                | *H. pylori*                                                            | Competitive inhibitor against *H. pylori* peptide deformylase, blocking substrate entrance                                                                                                                                 | [131]      |
| Origin          | Propolis type/plant source | Type of extract/isolated compound(s) | Species/cells                                         | Effect/stimulus                                                                 | References |
|-----------------|----------------------------|-------------------------------------|------------------------------------------------------|--------------------------------------------------------------------------------|------------|
| Brazil          | Green propolis/B. dracunculifolia | PEE                                 | C. albicans, C. tropicalis, C. krusei, and C. guilliermondii; adult volunteer patients showing symptoms of stomatitis | Inhibition of cell growth, C. albicans being the most sensitive and C. guilliermondii the most resistant, reduction of the number of Candida yeasts in the saliva | [141]     |
|                 | Green propolis/B. dracunculifolia; red propolis/D. ecastaphyllum | PEE                                 | T. rubrum, T. tonsurans, T. mentagrophytes, and T. mentagrophytes (ATCC 9533) (control) | Both samples which decrease cell growth, red PEE being more efficient than the green one | [143]     |
|                 |                           | PEE                                 | C. albicans strains SC5314 (wild type), CA14, and 353 A (wild type), female BALB/c mice | Inhibition of cell growth, C. albicans being the most sensitive and C. guilliermondii the most resistant, reduction of the number of Candida yeasts in the saliva | [150]     |
|                 |                           | gels, and cream obtained from the extract | C. albicans strains used were SC5314, CA14, BWP17, DAY286, 3153A, and 529L (wild type), female BALB/c mice (murine model of vulvovaginal candidiasis) | Inhibition of all three C. albicans morphogenetic types, several mutants in genes involved either in the morphological transitions or in the maintenance of a specific morphotype which are more sensitive to propolis | [151]     |
| Brazil          | Green propolis/B. dracunculifolia | PEE                                 | C. albicans (ATCC 90028), 29 C. albicans isolates from patients with vulvovaginal candidiasis | Inhibition of fungal growth, C. albicans from vulvovaginal candidiasis | [149]     |
|                 | Red propolis/D. ecastaphyllum | n-Hexane extract                    | C. albicans (ATCC 66396), C. glabrata (LMA 90–1085), and A. fumigatus (CBS 11326) | Antifungal activity against C. albicans and C. glabrata but only having a weak activity towards A. fumigatus | [143]     |
| France          | European propolis/Populus nigra | PEE, PWE, methanolic extract, and dichloromethane extract | C. albicans (ATCC 66396), C. glabrata (LMA 90–1085), and A. fumigatus (CBS 11326) | Antifungal activity against C. albicans and C. glabrata but only having a weak activity towards A. fumigatus | [133]     |
| Brazil          | Mediterranean propolis/Populus spp | PEE                                 | P. brasiliensis, peritoneal macrophages obtained from male BALB/c mice | Increase of fungalidal activity of macrophages against P. brasiliensis | [142]     |
| Czech Republic  | European propolis/Populus nigra | Dimethyl sulfoxide extract          | C. albicans, A. fumigatus, M. gypseum, and M. canis | Affecting the growth of the tested bacteria in different ways by different concentrations | [201]     |
| Portugal (Bragança and Leiria) | European propolis/Populus nigra | PEE                                 | C. albicans, T. rubrum, and A. fumigatus | Plant extracts not exhibiting relevant antifungal activity, but in general both propolis samples affecting the fungal growth | [140]     |
| Poland          | European propolis/Populus nigra and some species of Betula alba, Alnus glutinosa, Aesculus hippocastanum, and Fagus sylvatica | PEE                                 | 20 isolated C. albicans, 14 isolated C. glabrata, and 10 C. krusei | Inhibition of fungal growth | [147]     |
| Iran            | European propolis/Poplar spp., Ferula ovina | PEE                                 | C. albicans, C. tropicalis, C. kofye, C. krusei, M. globose, M. slofiae, and M. pachydermatis, all obtained from patients with clinical features of onychomycosis | Decrease of Ganfida and Malassezia strains growth, isolated from onychomycosis, even in the flucanazole-resistant strains | [205]     |
Table 7: Continued.

| Origin                  | Propolis type/plant source                  | Type of extract/isolated compound(s) | Species/cells                                                                 | Effect/stimulus                                                                 | References |
|-------------------------|---------------------------------------------|-------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------|------------|
| Brazil                  | Green propolis/B. dracunculifolius          | PEE and propolis microparticles      | 89 yeast strains from vaginal exudates of the vulvovaginal candidiasis patients: 58 C. albicans and 17 C. glabrata, 1 C. tropicalis, 8 C. guilliermondii, and 5 C. parapsilosis Xuophagous (G. candidum, L. elegans, P. nigrovirens, and S. commute) and phytopathogenic (A. niger, Fusarium sp., Macrophomina sp., P. notatum, and Rhodotorula spp.) | Inhibition of all yeasts growth by ethanol extract and propolis microparticles, with small variation, independent of the species of yeast | [144]      |
| Argentina               | Tropical region propolis/Salix humboldtiana, Pinus spp., Eucalyptus spp., and Populus spp. | PEE                                 |                                                                                | Inhibition of fungal growth                                                      | [146]      |
| Spain (Basque Country)  | European propolis/Populus nigra             | PEE and propylene glycol extract    | C. albicans (CECT 1394), S. cerevisiae (CECT 1383)                              | Inhibition of fungal growth                                                      | [145]      |
mechanism of CAPE. *H. pylori*, a major factor for gastrointestinal illnesses, contains the enzyme *H. pylori* peptide deformylase that catalyses the removal of formyl group from the N-terminus of nascent polypeptide chains. Since the action of this enzyme is essential for *H. pylori* survival, it is considered a promising therapeutic drug target. Results from absorption spectra and crystal structural characterization showed that CAPE is a competitive inhibitor of peptide deformylase, blocking the substrate entrance and preventing substrate from approaching the active site [131].

It has been suggested that the combination of propolis with other antibiotics would allow dose reduction of selected antibiotics, thus potentiating their effect. The antibacterial activity of Italian PEE in some clinically isolated Gram-positive strains, as well as the synergetic effect with some antibiotics, was assessed by Scassacchio et al. [56]. Italian PEE drastically increased the effect of ampicillin, gentamicin, and streptomycin and moderated the action of chloramphenicol, ceftriaxone, and vancomycin. No effect was observed when used simultaneously with erythromycin. Wojtczycka et al. [132] evaluated the *in vitro* antimicrobial activity of a Polish PEE against meticillin-sensitive *S. aureus* (MSSA) and meticillin-resistant *S. aureus* (MRSA) clinical isolates and also the combined effect of propolis with ten selected antistaphylococcal drugs. PEE displayed varying effectiveness against twelve *S. aureus* strains and potentiated the antimicrobial effect of eight antistaphylococcal against all tested strains. No synergism was observed in the case of ciprofloxacin and chloramphenicol. In another study, the effect of dichloromethane extract of French propolis against different human pathogenic bacterial strains was also tested. Although Gram-negative bacteria were not susceptible to the extract, a significant antibacterial activity against both meticillin-resistant and meticillin-susceptible *S. aureus* strains was observed [133]. The same was confirmed by Velikova et al. [28] using different PEE from Bulgaria, Greece, Turkey, and Algeria. All the samples showed a good antibacterial activity against *S. aureus* but a week or lacking effect against *E. coli*. Australian PEE from stingless bee *Tetragonula carbonaria* also inhibited the growth of *S. aureus*. Nevertheless, it was less active against *P. aeruginosa* [42]. The same was observed by Papachroni et al. [53] using PEE from Cameroon and Congo. Contrary to these studies, Katiccioglu and Mercan [134] showed that Turkish PEE was effective against Gram-negative bacteria like *E. coli*. Orsi et al. [135] investigated the possible synergism between Brazilian and Bulgarian propolis and antibiotics acting on DNA (ciprofloxacin and norfloxacin) and on metabolism (cotrimoxazole) in *Salmonella typhi*. Both samples had antibacterial activity, but no synergistic effect was detected.

Recently, the suitability of nanohydroxyapatite- (nano-HA-) based surfaces containing two Brazilian PEE (green and red ones) to prevent *S. aureus* bacterial growth and biofilm was studied. The nanoHA impregnated with the two highest concentrations (12 and 25 µg/mL) of red PEE showed a remarkable reduction of 99% in the number of viable bacteria, while nanoHA with green PEE at same concentrations showed a reduction of 45 and 61%. Moreover, the nanoHA impregnated with the highest concentration of red PEE was able to inhibit 80% of the staphylococcal biofilm formation [136].

Diverse studies show that as the composition of propolis varies from region to region, the antibacterial activity also displays some variations [59]. Susceptibility of different Gram-positive bacteria to PEE varies with the place of propolis collection [137]. The antibacterial effect was shown to be higher for samples from a wet-tropical rain forest-type climate. Other studies revealed the influence of propolis geographical origin on its antibacterial properties [57, 58, 138, 139]. Propolis from the north and centre of Portugal has a great activity against *S. aureus* [58, 140].

4.5.2. Antifungal Activity. Antifungal activity is also influenced by the chemical variation of propolis [59]. Several studies have shown the effect of propolis from different geographic origin against different fungi, particularly of clinical interest [141–145]. Quiroga et al. [146] demonstrated the antifungal activity of propolis from the northwest of Argentina, focusing their study on the environment and the development of agrochemicals with reduced economic costs, possibly containing propolis extracts and its isolated compounds, such as pinocembrin and galangin, as active principles.

Recently, Falcão et al. [140] screened the antifungal activity of Portuguese propolis and its potential floral sources *Populus x Canadensis* and *Cistus ladanifer* against Candida albicans, Trichophyton rubrum, and Aspergillus fumigatus. Plant extracts did not exhibit relevant antifungal activity; with exception of *T. rubrum*, but both propolis samples revealed similar antifungal activity, the highest being obtained against *T. rubrum* and the lowest against *A. fumigatus*. A sample of PEE from Poland showed a high fungicidal activity against *C. albicans*, *C. glabrata*, and *C. krusei* [147]. Recently, it was shown that different organic extracts of French propolis (PWE, PWE, methanolic extract, and dichloromethane extract) were effective against *C. albicans* and *C. glabrata* but only have a weak activity towards *A. fumigates* [133].

Brazilian PEE was proved to be active against several Candida strains (*C. albicans*, *C. tropicalis*, *C. krusei*, and *C. guilliermondii*), *C. albicans* being the most sensitive and *C. guilliermondii* the most resistant [141]. Brazilian green and red propolis display activity against different fungal species of *Trichophyton*, which cause dermatophytosis, red PEE being more efficient than the green one [143]. Also, it was shown that n-hexane extract of Brazilian red propolis did not induce resistance in *Candida* spp. in fact it was active against *Candida* spp. resistant to antifungal agents, like fluconazole [148]. Dota et al. [144] evaluated the *in vitro* antifungal activity of PEE and propolis microparticles (PMs) obtained from a sample from Argentina against clinical yeast isolates of importance in the vulvovaginal candidiasis. *C. albicans* and non-*C. albicans* were inhibited by PEE and PMs, with small variation. Additionally, it was shown that Brazilian green PEE has the ability to inhibit growth and biofilm formation by *C. albicans* from vulvovaginal candidiasis [149]. Another study showed fungicide action of propolis (PEE, PWE, propolis matriuscular microparticles (PMM), and propolis soluble dry extract after 6–8-hour treatment against all three
C. albicans morphotypes (yeast, pseudohyphae, and hyphae), PEE being the most potent followed by PSDE, PM, and PWE [150]. Brazilian propolis induces C. albicans cell death mediated via metacaspase, since the metacaspase mutant in C. albicans showed reduced sensitivity to propolis, and by the Ras pathway. Using C. albicans deletion libraries, it was possible to screen several mutants in genes involved either in the morphological transitions or in the maintenance of a specific morphotype that are more sensitive to propolis. To conclude the study, the authors also showed that propolis based gels and cream were partially able to control vulvovaginal candidiasis in a mouse model [151]. These studies [144] strongly indicate that propolis has a great potential to control vulvovaginal candidiasis, representing a promising alternative therapeutic strategy.

4.6. Antitumour Activity. Recognition of the hallmarks of cancer affects the search and development of new methods and therapeutic agents with a sufficiently large therapeutic window to kill tumour cells while sparing normal cells. In the last years, the natural product propolis has attracted a growing interest by a large number of researchers since it contains a variety of phytochemical compounds that may act through multiple pathways to reduce the development and other malignant characteristics of cancer cells.

Recently, several in vitro studies have demonstrated a cytotoxic action of propolis from different geographic origin and of some of its isolated compounds on various tumour cells. In vivo studies also show a potential in the development of new antitumor agents, since propolis administration to mammals (e.g., rats) does not lead to detectable side effects [3]. Briefly, this natural product can block specific oncogene signalling pathways, which in turn lead to a decrease in cell proliferation and growth and can also act by decreasing the cancer stem cell population, increasing apoptosis, exerting antiangiogenic effects, and modulating the tumour microenvironment [66, 152, 153]. Table 8 summarizes the antitumour activity of propolis from different geographic origin and its chemical constituents.

Some researchers showed the effect of different types of propolis and its constituents on cancer cell growth, proliferation, and apoptosis. The hexane extract of propolis from Thailand, collected by the stingless bee Trigona laeviceps, which has a different behavior in propolis collection compared to the honey bees, exerts antiproliferative activity against five tested cancer cell lines (Chago, KATO-III, SW620, BT474, and Hep-G2) but not against the normal cell lines tested (HS27 fibroblast and CH-liver) [5]. A sample of PEE from Poland inhibited human malignant melanoma (Me45) and colorectal cancer (HCT 116) cells growth, as well as reduced cell size [154]. Other studies reported the antitumor activity of Brazilian PEE [155–158] which regulate the protein expression of cyclin D1, B1 and cyclin dependent kinase (CDK) as well as p21 in human prostate cancer cells, significantly affecting proliferation [158].

Although propolis containing CAPE is different from those with artepillin C, it is possible to obtain a similar inhibitory effect from both types. The effect of CAPE on different cancer cell lines was analysed and many of its effects have been shown to be mediated through inhibition of NF-κB [66, 159]. CAPE can inhibit the proliferation of the colorectal cell line SW480 by decreasing the β-catenin, c-myc, and cyclin D1 protein expression [160]. Chuu et al. [161] observed that CAPE suppressed the proliferation of LNCaP, DU-145, and PC-3 human prostate cancer cells in a dose-dependent manner and also inhibited the tumour growth of LNCaP xenografts in nude mice. It was suggested that it acted through inhibition of p70S6K (an intermediary of the PI3K/AKT pathway responsible for the protein synthesis) and some Akt signalling networks. Wu et al. [162] demonstrated that CAPE inhibits in vitro and in vivo MCF-7 and MDA-MB-231 tumour growth without much effect on normal mammary cells by reducing the expression of growth and transcription factors, including NF-κB. Recently, it was demonstrated that CAPE effect on genes that are associated with tumour cell growth and survival is related in part to its role as a histone deacetylase inhibitor [163].

As previously said, propolis can also act by decreasing the cancer stem cell population. Using the putative CD44 (+)/CD24 (−/low) breast cancer stem cells able to generate mammospheres from single cells, Omene et al. [164] showed that CAPE caused a dose-dependent inhibition of cancer stem cells self-renewal, progenitor formation, and clonal growth.

Concerning cell death, some in vitro studies showed different sensitivities of tumour cells to propolis extracts. PWE from Iraq inhibits the proliferation of HL-60 cells and leads to downregulation of Bcl-2 and activation of Bax [13]. Alizadeh et al. [165] investigated the protective effects of Iranian PEE on N-methyl-N-nitro-N-nitrosoguanidine-(MNNG-) initiated gastric cancer in rats. Results showed that tumour incidence, the number of lesions, structural abnormalities, and beta-catenin of the animals group treated with PEE significantly declined compared with the control. PEE also induced the expression of proapoptotic Bax and reduced antiapoptotic Bcl-2 expression. Propolis inhibits colony formation potential and promotes necrotic changes in HCT-116 cells and decreases mitotic cells and increases p53 and Ki-67 expression in HCT-116 tumor-bearing mice [13]. Szliskak’s group have performed many studies to analyze the antitumour effect of different propolis and its constituents on prostate cancer cells (LNCaP and DU145) [166–168]. Brazilian green PEE sensitized these cells to TRAIL-induced death, enhanced the expression of TRAIL-R2, and decreased the activity of NF-κB in LNCaP cells [167]. Cotreatment of TRAIL with artepillin C induced the significant activation of caspase-8 and caspase-3, as well as a significant disruption of the mitochondrial membrane potential [169]. Many studies have been conducted to understand the pathways involved in the apoptotic effect of CAPE. CAPE induces cell cycle arrest and apoptosis and reduces expression of NF-κB in MDA-MB-231 and MCF-7 human breast cancer cells [162]. In PC3 prostate cancer cells, CAPE induced apoptosis in a dose-dependent manner that was associated with the loss of expression of the inhibitors of apoptosis: cIAP-1, cIAP-2, and XIAP [170]. Cavaliere et al. [171] showed that CAPE treatment...
| Origin | Propolis type/plant source | Type of extract/isolated compound(s) | Species/cells | Effect |
|-------|---------------------------|-------------------------------------|---------------|--------|
| Thailand | Propolis from stingless bee Trigona laeviceps | Hexane extract | Colon (SW620), breast (BT474), hepatic (Hep-G2), lung (Chago), and stomach (Kato-III) cells, Normal cell lines (liver (CH-liver) and fibroblast (HS-27)) | High antiproliferative activity against the five cancer cell lines and low cytotoxic activity on the normal cell lines [5] |
| Poland | European propolis/Populus nigra and some species of Betula alba, Alnus glutinosa, Aesculus hippocastanum, and Fagus sylvatica | PEE Human malignant melanoma cell line Me45; colorectal cancer cell line HCT116 | Inhibition of cell growth and reduction of cell size of the tested cancer cells [154] |
| Synthesized | Characteristic of propolis from the Pacific region, Thailand, Africa, Australia, and Brazil | Prenylated flavanones | Prostate cancer cell lines PC-3 and DU-145, Human hepatoma cell line Hep-3B | Induction of more potent cytotoxicity against the PC-3 cell line than 5-fluorouracil; induction of apoptosis [45] |
| Brazil | Characteristic of Brazilian propolis | Drupanin, baccharin ((E)-3-prenyl-4-(2,3-dihydrocinnamoyloxy)cinnamic acid) and artepillin C (isolated from PEE of propolis) | Human leukemia cell line HL-60, colon cancer cell line SW480 | Inhibition of cell growth; promotion of morphological changes and nucleosomal DNA fragmentation (artepillin C > baccharin > drupanin) [208] |
| Red propolis/D. ecastaphyllum | Methanolic extract | Human pancreatic cancer cells (PANC-1) | Killing 100% of PANC-1 cells in the nutrient-deprived condition [157] |
| Green propolis/B. dracunculifolia | PEE | DU145 and PC-3 cell lines, telomerase-immortalized primary human prostate cancer-derived cell (RC-58T/h/SA#4), and primary human prostate epithelial cells (PrEC) | Inhibition of human prostate cancer cells proliferation by regulating the expression of cyclin D1, B1, and CDK, p21, p27, and p16; decrease in tumorigenesis, reduction of the number of mitotic cells and proliferating cell nuclear antigen (PCNA)-positive cells in C6 glioma [207] |
| Green propolis/B. dracunculifolia | Baccharin, beturetol, kaempferide, isosakuranetin, and drupanin (isolated from PEE) PWE Female Wistar rats | Induction of apoptosis in tube-forming endothelial cells through the inactivation of the survival signal ERK1/2 and by the activation of caspase-3 [175] |
| Green propolis/B. dracunculifolia | PEE HUVEC cells | Inhibition of angiogenesis in N-butyl-(4-hydroxybutyl) nitrosamine- (BBN-) induced rat bladder cancer [210] |
| Red propolis/D. ecastaphyllum | PEE | Human immortalized endothelial-like cell line EA.hy926, renal cell carcinoma cell line RCC4, and mouse embryonic stem cell line CGR | Reduction of migration and sprouting of endothelial cells and attenuation of new blood vessels formation; decrease in the differentiation of embryonic stem cells into CD31-positive cells; decrease in HIF1-alpha protein accumulation which attenuates VEGF gene expression, increases the von Hippel-Lindau (pVHL)-dependent proteasomal degradation of HIF1-alpha, and downregulates Cdc42 protein expression [211] |
| Origin                  | Propolis type/plant source                  | Type of extract/isolated compound(s) | Species/cells                                                                 | Effect                                                                                                                                  | References |
|------------------------|--------------------------------------------|-------------------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|------------|
| Brazil                 | Green propolis/B. dracunculifolia          | PEE                                 | Human umbilical vein endothelial cells (HUVECs), NF1-deficient MPNST (S-462), and NF2-deficient schwannoma (HEI-93) cell lines Female nu/nu mice | Blocking PAK1 signaling selectively, without affecting AKT; suppressing almost completely the growth of human neurofibromatosis tumor xenografts in mice | [156]      |
| Synthesized            | Brazilian propolis                         | Artepillin C                        |                                                                                                           |                                                                                                                                         |            |
| Brazil                 | Purchased: Wako Pure Chemicals Industries (Osaka, Japan) |                           |                                                                                                           |                                                                                                                                         |            |
| Brazil                 | Green propolis/B. dracunculifolia          | PEE                                 | HUVECs Female ICR mice                                                        | Reduction of the number of newly formed vessels in vivo; Suppression of HUVECs proliferation and inhibition of tube formation             | [174]      |
| Brazil                 | Purchased: Alexis Biochemicals (San Diego, CA, USA) |                           |                                                                                                           |                                                                                                                                         | [167]      |
| Purchased: Wako Pure Chemicals (Osaka, Japan) |                           |                                                                                                           |                                                                                                                                         |                                                                                                                                         |            |
| Brazil                 | Green propolis/B. dracunculifolia          | Artepillin C                        | LNCaP cell line                                                              | Sensitizing TRAIL-resistant LNCaP cells to TRAIL-induced apoptosis; Induction of a significant disruption of ΔΨm                      |            |
| Brazil                 | Red propolis/D. cestaphylum                | Artepillin C                        | MCF-7 cell line                                                              | Reducing cell viability through induction of mitochondrial dysfunction, caspase-3 activity, and DNA fragmentation and increase in expression of CCAAT/enhancer binding protein homologous protein (CHOP) | [212]      |
| Brazil                 | Purchased: Api Co. Ltd., Gifu, Japan       | CAPE                                | LNCaP 104-S, DU-145, and PC-3 cell lines Male BALB/c mice                     | Suppressing the growth of LNCaP, DU-145, and PC-3 and inhibiting the tumor growth of LNCaP xenografts, possible inhibition of p70S6K and some Akt signaling networks | [161]      |
| Brazil                 | Purchased: Sigma Aldrich Co.               | CAPE                                | Breast cell lines MDA-MB-231, MCF-7, MCF-10A, and MCF-12A Bowine capillary endothelial (BCE) cells Female (Ncr-nu-nu) mice | Suppression of proliferation, colony formation, and cell cycle progression, decrease in protein expression of cyclin D1, cyclin E, SKP2, c-Myc, Akt1, Akt2, Akt3, total Akt, mTOR, and Bcl-2, Bb, as well as phosphorylation of Bb, ERK1/2, Akt, mTOR, GSK3α, GSK3β, and PDK1, and increase in KLF6 and p21<sub>WAF1/CIP1</sub> protein expression | [213]      |
|                       | Characteristic of European propolis        |                                                                                                           | Breast cancer cell lines MDA-MB-231, MCF-7, and SKBR3                         | Promotion of an accumulation of acetylated histone proteins in MCF-7 (ER+) and MDA-MB-231 (ER−/PR−/Her2−); decrease of ER and PR in MCF-7 cells and upregulation of ER and decrease of EGF in MDA-MB-231 cells; reduction of Her2 protein in SKBR3 (Her2+) cells | [162]      |
|                       |                                                                                                           | Suppression of cell proliferation and colony formation; decrease of G1 phase cell population, increase of G2/M phase cell population; induction of apoptosis; decrease of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr308, GSK3β, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FOXO3a Thr32, NF-xB, phospho-NF-xB Ser536, Bb, phospho-Rb Ser870/871, Skp2, and cyclin D1; and increase of cell cycle inhibitor p27<sub>KIP1</sub> |                                                                                                                                         |            |
|                       |                                                                                                           | Inhibition of cancer stem cells self-renewal, progenitor formation, and clonal growth and decrease of CD44 levels |                                                                                                                                         | [214]      |
|                       |                                                                                                           | Suppression of the adhesion and invasion potential of the cells by inhibiting completely the expression of MMP-2 and metalloproteinase-9 (MMP-9) and the NF-xB |                                                                                                                                         | [164]      |
|                       |                                                                                                           | Decrease of MMP and tissue inhibitor metalloproteinase-2 (TIMP-2) mRNA levels; downregulation of MMP-2 and MMP-9 expression; inhibition of MMP-2 activity; decrease of invasion, motility, cell migration, and colony formation |                                                                                                                                         | [172]      |
|                       |                                                                                                           |                                                                                                           |                                                                                                                                         | [215]      |
| Origin                  | Propolis type/plant source          | Type of extract/isolated compound(s) | Species/cells | Effect                                                                 | References |
|------------------------|-------------------------------------|-------------------------------------|---------------|------------------------------------------------------------------------|------------|
| Turkey                 | Mediterranean propolis/Populus spp., Eucalyptus spp., and Castanea sativa | PEE                                 | MCF-7 cell line | Increase of apoptosis through the caspase pathway                       | [216]      |
| Iraq                   | European propolis/Populus nigra     | PWE                                 | HL-60 cell line, colon cancer cell HCT-116, Female athymic Fox N1-nu/nu mice | Inhibition of HL-60 cells proliferation and induction of apoptosis by downregulating Bcl-2 protein and upregulating Bax; inhibition of HCT-116 cells colony formation potential and promotion of necrotic changes; decrease of mitotic cells and increase of p53 and Ki-67 expression in HCT-116 tumor-bearing mice | [13]       |
| Iran                   | European propolis/Poplar spp., Ferula ovina | PEE                                 | Male Wistar rats | Decrease of tumour incidence, number of lesions, structural abnormalities, and beta-catenin and induction of proapoptotic Bax expression and reduction of antiapoptotic Bcl-2 expression | [165]      |
| Provided by Wako Pure Chemicals (Osaka, Japan) | Characteristic of Brazilian propolis | Artepillin C                        | LNCaP cell line | Induction of caspase-8 and caspase-3 activation and disruption of mitochondrial membrane potential by a cotreatment with TRAIL and artepillin C | [169]      |
| Purchased              | Characteristic of European propolis | CAPE                                | MCF-7 cell line | Induction of apoptosis via Fas signal; induction of Bax protein and activation of caspases and MAPK family proteins p38 and JNK | [217]      |
| Purchased: Calbiochem (San Diego, CA, USA) | Characteristic of European propolis | CAPE                                | Lymphoblastoid cell line PI104 | Induction of apoptosis through phosphatidylinositol (PS) exposure and nuclear fragmentation; Increase of sub-G1 DNA content; downregulation of survivin and Bcl-2 expression and increase of BAX proteins levels; induction of mitochondrial membrane potential (ΔΨm) collapse; induction of cytochrome c release from mitochondria and induction of caspases 3, 7, and 9 activation | [171]      |
| China; Purchased: Api Co. Ltd. (Gifu, Japan) | European propolis/Populus nigra | PEE                                 | HUVECs         | Inhibition of VEGF expression                                           | [179]      |
| Korea; Synthesized     | European propolis/Populus nigra     | PEE                                 | Fertilized chicken eggs, Cultured pulmonary arterial endothelial (CPAE) cells | Inhibition of angiogenesis in chick embryo choioallantoic membrane and inhibition of CPAE cells proliferation | [176]      |
| Portugal: (Serra de Borens and Fundio); (Anga do Heroismo, Azores) | European propolis/Populus nigra | Methanolic extract and hexane, chloroform, and residual ethanol extract fractions obtained from the PEE | Human colorectal adenocarcinoma cell line HCT-15 | Inhibition tumor cells growth exhibiting selective toxicity against malignant cells compared to normal cells | [64]       |
|                        |                                     | PEE and hexane, chloroform, and residual ethanol extract fractions obtained from the PEE | Human colorectal adenocarcinoma cell line HCT-15 | All the samples exhibiting cytotoxic effect against tumor cells; chloroform fraction decreasing cell viability, promoting cell death, and disturbing tumor cell glycolytic metabolism | [218]      |
of lymphoblastoid cell line PL104 induced apoptosis through the mitochondrial intrinsic pathway.

It has been known that cancer microenvironment is very important for carcinogenesis and it consists of stromal, endothelial, immune, and cancer cells. Natural products, like propolis and their constituents, have been shown to interfere with this symbiosis. It was demonstrated by Lee et al. [172] that CAPE could effectively suppress the adhesion and invasion potential of human hepatocellular carcinoma cells (SK-Hep1) by inhibiting the expression of MMP-2 and MMP-9 and NF-κB.

Angiogenesis has a crucial role in tumour growth due to the requirement of oxygen and nutrients to sustain rapid uncontrolled proliferation and metastatization. Both tumour and stromal cells can secrete proangiogenic factors that stimulate the formation and maintenance of new vessels, such as vascular endothelial growth factor (VEGF) [173]. Brazilian PEE could significantly reduce the number of newly formed vessels and suppress the proliferation of umbilical vein endothelial cells (HUVECs) [174], this antiangiogenic effect being mainly mediated via inducing apoptosis in tube-forming endothelial cells through the inactivation of the survival signal ERK1/2 [175]. Yun et al. [176] observed that CAPE inhibited angiogenesis using the in vivo assay chick embryo chorioallantoic membrane (CAM). CAPE also suppresses VEGF formation by MDA-MB-231 cells and formation of capillary-like tubes by endothelial cells [162, 177]. Extracts of propolis containing artepillin C and CAPE significantly reduced the newly formed vessels and expression of MMPs and VEGF production from various cells [178] and, in accordance with this study, Izuta et al. [179] described that CAPE promotes inhibition of VEGF expression in HUVEC cells.

The first study on the antitumor activity of Portuguese propolis was only performed in 2010. Using normal and cancerous renal cells derived from human renal cell carcinoma (RCC) patients, in addition to A-498 cell line, Valente et al. [64] showed that methanolic extract of Portuguese propolis exhibited selective toxicity against malignant cells compared to normal cells and in vitro RCC growth was strongly inhibited. Recently, our group demonstrated the antitumour and antiangiogenic activity of the ethanol extract of Pereiro propolis (P10.EE), collected in the district of Guarda, Portugal. P10.EE affects cell viability of different tumour cells, MDA-MB-231 (breast) and DU145 (prostate) being two of the most sensitive ones, but was less cytotoxic against non-tumour cells and fibroblasts. Also, it significantly decreased MDA-MB-231 and DU145 cell proliferation and migration along time, with cell cycle changes, and increased cell death. The significant increase observed in glucose consumption and lactate production could be explained in MDA-MB-231 by an increased expression of hypoxia inducible factor-1α, pyruvate dehydrogenase kinase, glucose transporter 1, lactate dehydrogenase, and carbonic anhydrase. Furthermore, P10.EE induced a decrease in HBMECs total biomass and proliferation and decreased vessel sprouting in the chicken chorioallantoic membrane [23].

5. Conclusions

From ancient to modern times, herbs and other plant products have been widely used as medicinal agents, first in folk medicine and other activities in many parts of the world and later developed and improved on a scientific basis into drugs that are used in the health system. Propolis is one of the few natural products that has maintained its popularity over a long period of time. As reviewed here, propolis contains a broad spectrum of compounds that may be useful in the treatment of different pathological conditions. In fact there is much literature that deals with the in vitro and in vivo biological properties of propolis. This wide range of bioactivities, the continuous discovery of new compounds, the long history of propolis use, and its safety profile make propolis a potential candidate for drug discovery that may be useful in several clinical scenarios. Nevertheless, it is necessary to make an effort to standardize propolis composition since it seems that propolis biological properties and chemical composition not only are variable but also are strictly linked. In our opinion, propolis extracts may be important economically and would allow a relatively inexpensive treatment in different diseases; however, to promote its use in modern medicine, it will be necessary to identify and isolate the bioactive compounds to be tested separately or in combination with other drugs already available.

Drug discovery does not consist only of the isolation of bioactive lead compounds from the natural sources. In fact, this process continues outside the academic laboratories through preclinical studies followed by clinical trials. Thus, despite the in vitro and in vivo assays, which provide new valuable information on propolis biological properties and mechanisms of action, it will be necessary to analyse the effectiveness of propolis clinically, to complement the basic research available, and to evaluate the potential of propolis in human health promotion.

Abbreviations

CAPE: Caffeic acid phenethyl ester
PEE: Propolis ethanol extract
PWE: Propolis water extract
RNS: Reactive nitrogen species
ROS: Reactive oxygen species
VEGF: Vascular endothelial growth factor.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] M. Gordaliza, “Natural products as leads to anticancer drugs,” Clinical and Translational Oncology, vol. 9, no. 12, pp. 767–776, 2007.
[2] D. J. Newman and G. M. Cragg, “Natural products as sources of new drugs over the last 25 years,” Journal of Natural Products, vol. 70, no. 3, pp. 461–477, 2007.
Evidence-Based Complementary and Alternative Medicine

[3] M. A. E. Watanabe, M. K. Amarante, B. J. Conti, and J. M. Sforcin, “Cytotoxic constituents of propolis inducing anticancer effects: a review,” Journal of Pharmacy and Pharmacology, vol. 63, no. 11, pp. 1378–1386, 2011.

[4] K.-H. Lee, “Current developments in the discovery and design of new drug candidates from plant natural product leads,” Journal of Natural Products, vol. 67, no. 2, pp. 273–283, 2004.

[5] S. Umthong, P. Phuwapsrainsarn, S. Puthong, and C. Chanchao, “In vitro antiproliferative activity of partially purified Trigona laeiceps propolis from Thailand on human cancer cell lines,” BMC Complementary and Alternative Medicine, vol. 11, article 37, 2011.

[6] J. M. Sforcin and V. Bankova, “Propolis: is there a potential for the development of new drugs?” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 253–260, 2011.

[7] M. A. E. Watanabe, M. K. Amarante, B. J. Conti, and J. M. Sforcin, “Cytotoxic constituents of propolis inducing anticancer effects: a review,” Journal of Pharmacy and Pharmacology, vol. 63, no. 11, pp. 1378–1386, 2011.

[8] Y. Barflak, O. Değer, M. Çolak, S. K. Karatayli, A. M. Bozdayi, and F. Yücesan, “Effect of Turkish propolis extracts on proteome of prostate cancer cell line,” Proteome Science, vol. 9, article 74, 2011.

[9] V. Bankova, “Chemical diversity of propolis and the problem of standardization,” Journal of Ethnopharmacology, vol. 100, no. 1-2, pp. 114–117, 2005.

[10] V. S. Bankova, S. L. de Castro, and M. C. Marcucci, “Propolis: recent advances in chemistry and plant origin,” Apidologie, vol. 31, no. 1, pp. 3–15, 2000.

[11] S. M. Cardoso, M. Ribeiro, I. L. Ferreira, and A. Cristina Rego, “Northeast Portuguese propolis protects against staurosporine and hydrogen peroxide-induced neurotoxicity in primary cortical neurons,” Food and Chemical Toxicology, vol. 49, no. 11, pp. 2862–2868, 2011.

[12] H. Fokt, A. Pereira, A. M. Ferreira, A. Cunha, and C. Aguiar, “How do bees prevent hive infections? The antimicrobial properties of propolis,” in Current Research, Technology and Educational Topics in Applied Microbiology and Microbial Biotechnology, A. Mendez-Vilas, Ed., vol. 1 of Microbiology Book Series—Number 2, pp. 481–493, 2010.

[13] G. M. Sulaiman, A. H. Ad’hiah, K. W. Al-Sammarrae et al., “Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo,” Food and Chemical Toxicology, vol. 50, no. 5, pp. 1632–1641, 2012.

[14] N. Orsolic, S. Terzic, Z. Mihaljevic, L. Sver, and I. Basic, “Effects of local administration of propolis and its polyphenolic compounds on tumor formation and growth,” Biological and Pharmaceutical Bulletin, vol. 28, no. 10, pp. 1928–1933, 2005.

[15] S. Castaldo and F. Capasso, “Propolis, an old remedy used in modern medicine,” Fitoterapia, vol. 73, supplement 1, pp. S1–S6, 2002.

[16] G. A. Burdock, “Review of the biological properties and toxicity of bee propolis (propolis),” Food and Chemical Toxicology, vol. 36, no. 4, pp. 347–363, 1998.

[17] M. L. Khalil, “Biological activity of bee propolis in health and disease,” Asian Pacific Journal of Cancer Prevention, vol. 7, no. 1, pp. 22–31, 2006.

[18] J. B. Daleprane, V. da Silva Freitas, A. Pacheco et al., “Anti-atherogenic and anti-angiogenic activities of polyphenols from propolis,” Journal of Nutritional Biochemistry, vol. 23, no. 6, pp. 557–566, 2012.

[19] A. H. Banskota, Y. Tezuka, and S. Kadota, “Recent progress in pharmacological research of propolis,” Phytotherapy Research, vol. 15, no. 7, pp. 561–571, 2001.

[20] S. I. Falcão, M. Vilas-Boas, L. M. Estevinho, C. Barros, M. R. M. Domingues, and S. M. Cardoso, “Phenolic characterization of Northeast Portuguese propolis: usual and unusual compounds,” Analytical and Bioanalytical Chemistry, vol. 396, no. 2, pp. 887–897, 2010.

[21] S. I. Falcão, N. Vale, P. Gomes et al., “Phenolic profiling of Portuguese propolis by LC-MS spectrometry: uncommon propolis rich in flavonoid glycosides,” Phytochemical Analysis, vol. 24, no. 4, pp. 309–318, 2013.

[22] L.-P. Sun, A.-L. Chen, H.-C. Hung et al., “Chrysins: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis,” Journal of Agricultural and Food Chemistry, vol. 60, no. 47, pp. 11748–11758, 2012.

[23] R. Silva-Carvalho, V. Miranda-Gonçalves, A. M. Ferreira et al., “Antitumoural and antiangiogenic activity of Portuguese propolis in vitro and in vivo models,” Journal of Functional Foods, vol. 11, pp. 160–171, 2014.

[24] M. P. Popova, K. Graikou, I. Chinou, and V. S. Bankova, “GC-MS profiling of diterpene compounds in Mediterranean propolis from Greece,” Journal of Agricultural and Food Chemistry, vol. 58, no. 5, pp. 3167–3176, 2010.

[25] Ö. G. Çelemli, F. Hatjina, L. Charistos, A. Schiesser, and A. Özkirim, “More insight into the chemical composition of Greek propolis: differences and similarities with Turkish propolis,” Zeitschrift für Naturforschung C, vol. 68, no. 11-12, pp. 429–438, 2013.

[26] V. Bankova, M. Popova, S. Bogdanov, and A.-G. Sabatinii, “Chemical composition of European propolis: expected and unexpected results,” Zeitschrift für Naturforschung Section C, vol. 57, no. 5-6, pp. 530–533, 2002.

[27] M. Popova, B. Trusheva, D. Antonova et al., “The specific chemical profile of Mediterranean propolis from Malta,” Food Chemistry, vol. 126, no. 3, pp. 1431–1435, 2011.

[28] M. Velikova, V. Bankova, K. Sorkun, S. Houcine, I. Tsvetkova, and A. Kujumgiev, “Propolis from the Mediterranean region: chemical composition and antimicrobial activity,” Zeitschrift für Naturforschung C, vol. 55, no. 9-10, pp. 790–793, 2000.

[29] S. Silici, M. Ünlü, and G. Vardar-Ünlü, “Antibacterial activity and phytochemical evidence for the plant origin of Turkish propolis from different regions,” World Journal of Microbiology and Biotechnology, vol. 23, no. 12, pp. 1797–1803, 2007.

[30] N. Duran, M. Muz, G. Culha, G. Duran, and B. Ozer, “GC-MS analysis and antileishmanial activities of two Turkish propolis types,” Parasitology Research, vol. 108, no. 1, pp. 95–105, 2011.

[31] A. L. Piccinelli, T. Mencherini, R. Celano et al., “Chemical composition and antioxidant activity of Algerian propolis,” Journal of Agricultural and Food Chemistry, vol. 61, no. 21, pp. 5080–5088, 2013.

[32] Y. K. Park, S. M. Alencar, and C. L. Aguiar, “Botanical origin and chemical composition of Brazilian propolis,” Journal of Agricultural and Food Chemistry, vol. 50, no. 9, pp. 2502–2506, 2002.

[33] C. O. da Silva Frozza, C. S. C. Garcia, G. Gambato et al., “Chemical characterization, antioxidant and cytotoxic activities of Brazilian red propolis,” Food and Chemical Toxicology, vol. 52, pp. 137–142, 2013.

[34] A. Daugsch, C. S. Moraes, P. Fort, and Y. K. Park, “Brazilian red propolis—chemical composition and botanical origin,”
Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 4, pp. 435–441, 2008.

[35] B. B. Silva, P. L. Rosalen, J. A. Curu et al., “Chemical composition and botanical origin of red propolis, a new type of Brazilian propolis,” Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 3, pp. 313–316, 2008.

[36] O. Cuesta-Rubio, B. A. Frontana-Urbe, T. Ramirez-Apan, and J. Cardenas, “Polyisoprenylated benzophenones in Cuban propolis: biological activity of nemorosone,” Zeitschrift für Naturforschung C, vol. 57, no. 3-4, pp. 372–378, 2002.

[37] B. Trusheva, M. Popova, H. Naydenski, I. Tsvetkova, J. G. Rodriguez, and V. Bankova, “New polyisoprenylated benzophenones from Venezuelan propolis,” Fitoterapia, vol. 75, no. 7-8, pp. 683–689, 2004.

[38] F. A. Tomás-Barberán, C. García-Viguera, P. Vit-Olivier, F. Ferreres, and F. Tomás-Lorente, “Phychemical evidence for the botanical origin of tropical propolis from Venezuela,” Phytochemistry, vol. 34, no. 1, pp. 191–196, 1993.

[39] A. Abu-Mellal, N. Koolaji, R. K. Duke, V. H. Tran, and C. C. Duke, “Prenylated cinnameate and stilbenes from Kangooro Island propolis and their antioxidant activity,” Phytochemistry, vol. 77, pp. 251–259, 2012.

[40] V. H. Tran, R. K. Duke, A. Abu-Mellal, and C. C. Duke, “Propolis with high flavonoid content collected by honey bees from Acacia paradoxa,” Phytochemistry, vol. 81, pp. 126–132, 2012.

[41] E. L. Ghisalberti, P. R. Jefferies, R. Lanteri, and J. Matisons, “Constituents of propolis,” Experientia, vol. 34, no. 2, pp. 157–158, 1978.

[42] C. F. Massaro, M. Katouli, T. Grkovic et al., “Anti-staphylococcal activity of C-methyl flavanones from propolis of Australian stingless bees (Tetragona carbonaria) and fruit resins of Corymbia torelliana (Myrtaceae),” Fitoterapia, vol. 95, pp. 247–257, 2014.

[43] S. Kumazawa, H. Goto, T. Hamasaka, S. Fukumoto, T. Fujimoto, and T. Nakayama, “A new prenylated flavonoid from propolis collected in Okinawa, Japan,” Bioscience, Biotechnology and Biochemistry, vol. 68, no. 1, pp. 260–262, 2004.

[44] S. Inui, T. Hosoya, and S. Kumazawa, “Hawaiian propolis: comparative analysis and botanical origin,” Natural Product Communications, vol. 9, no. 2, pp. 165–166, 2014.

[45] C.-N. Chen, C.-J. Hsiao, S.-S. Lee et al., “Chemical modification and anticancer effect of prenylated flavanones from Taiwanese propolis,” Natural Product Research, vol. 26, no. 2, pp. 116–124, 2012.

[46] B. Trusheva, M. Popova, E. B. Koendhori, I. Tsvetkova, C. Naydenski, and V. Bankova, “Indonesian propolis: chemical composition, biological activity and botanical origin,” Natural Product Research, vol. 25, no. 6, pp. 606–613, 2011.

[47] F. Li, S. Alwele, H. Zhang, Y. Tetzka, H. Esumi, and S. Kadota, “Chemical constituents of propolis from Myanmar and their preferential cytotoxicity against a human pancreatic cancer cell line,” Journal of Natural Products, vol. 72, no. 7, pp. 1283–1287, 2009.

[48] S. Athikomkulchai, S. Alwele, N. Ruangrungsri, S. Ruchirawat, and S. Kadota, “Chemical constituents of Thai propolis,” Fitoterapia, vol. 88, pp. 96–100, 2013.

[49] V. S. Bankova, R. S. Christov, and A. D. Tejera, “Lignans and other constituents of propolis from the canary islands,” Phytochemistry, vol. 49, no. 5, pp. 1411–1415, 1998.

[50] A. Petrova, M. Popova, C. Kuzmanova et al., “New biologically active compounds from Kenyan propolis,” Fitoterapia, vol. 81, no. 6, pp. 509–514, 2010.

[51] M. Popova, R. Dimitrova, H. T. Al-Lawati, I. Tsvetkova, H. Naydenski, and V. Bankova, “Omanci propolis: chemical profiling, antibacterial activity and new propolis plant sources,” Chemistry Central Journal, vol. 7, no. 1, article 158, 2013.

[52] A. I. Rushdi, N. Adgaba, N. I. Bayaqqoob et al., “Characteristics and chemical compositions of propolis from Ethiopia,” SpringerPlus, vol. 3, no. 1, p. 253, 2014.

[53] B. Trusheva, M. Popova, H. Naydenski, I. Tsvetkova, J. G. Rodriguez, and V. Bankova, “New polyisoprenylated benzophenones from Venezuelan propolis,” Fitoterapia, vol. 75, no. 7-8, pp. 683–689, 2004.

[54] F. A. Tomás-Barberán, C. García-Viguera, P. Vit-Olivier, F. Ferreres, and F. Tomás-Lorente, “Phychemical evidence for the botanical origin of tropical propolis from Venezuela,” Phytochemistry, vol. 34, no. 1, pp. 191–196, 1993.

[55] A. Abu-Mellal, N. Koolaji, R. K. Duke, V. H. Tran, and C. C. Duke, “Prenylated cinnameate and stilbenes from Kangooro Island propolis and their antioxidant activity,” Phytochemistry, vol. 77, pp. 251–259, 2012.

[56] V. H. Tran, R. K. Duke, A. Abu-Mellal, and C. C. Duke, “Propolis with high flavonoid content collected by honey bees from Acacia paradoxa,” Phytochemistry, vol. 81, pp. 126–132, 2012.

[57] E. L. Ghisalberti, P. R. Jefferies, R. Lanteri, and J. Matisons, “Constituents of propolis,” Experientia, vol. 34, no. 2, pp. 157–158, 1978.

[58] C. F. Massaro, M. Katouli, T. Grkovic et al., “Anti-staphylococcal activity of C-methyl flavanones from propolis of Australian stingless bees (Tetragonula carbonaria) and fruit resins of Corymbia torelliana (Myrtaceae),” Fitoterapia, vol. 95, pp. 247–257, 2014.

[59] S. Kumazawa, H. Goto, T. Hamasaka, S. Fukumoto, T. Fujimoto, and T. Nakayama, “A new prenylated flavonoid from propolis collected in Okinawa, Japan,” Bioscience, Biotechnology and Biochemistry, vol. 68, no. 1, pp. 260–262, 2004.

[60] S. Inui, T. Hosoya, and S. Kumazawa, “Hawaiian propolis: comparative analysis and botanical origin,” Natural Product Communications, vol. 9, no. 2, pp. 165–166, 2014.

[61] C.-N. Chen, C.-J. Hsiao, S.-S. Lee et al., “Chemical modification and anticancer effect of prenylated flavanones from Taiwanese propolis,” Natural Product Research, vol. 26, no. 2, pp. 116–124, 2012.

[62] B. Trusheva, M. Popova, E. B. Koendhori, I. Tsvetkova, C. Naydenski, and V. Bankova, “Indonesian propolis: chemical composition, biological activity and botanical origin,” Natural Product Research, vol. 25, no. 6, pp. 606–613, 2011.

[63] F. Li, S. Alwele, H. Zhang, Y. Tetzka, H. Esumi, and S. Kadota, “Chemical constituents of propolis from Myanmar and their preferential cytotoxicity against a human pancreatic cancer cell line,” Journal of Natural Products, vol. 72, no. 7, pp. 1283–1287, 2009.

[64] S. Athikomkulchai, S. Alwele, N. Ruangrungsri, S. Ruchirawat, and S. Kadota, “Chemical constituents of Thai propolis,” Fitoterapia, vol. 88, pp. 96–100, 2013.

[65] V. S. Bankova, R. S. Christov, and A. D. Tejera, “Lignans and other constituents of propolis from the canary islands,” Phytochemistry, vol. 49, no. 5, pp. 1411–1415, 1998.

[66] A. Petrova, M. Popova, C. Kuzmanova et al., “New biologically active compounds from Kenyan propolis,” Fitoterapia, vol. 81, no. 6, pp. 509–514, 2010.
V. Sosa, T. Moliné, R. Somoza, R. Paciucci, H. Kondoh, and M. T. B. Salmon, B. A. Evert, B. Song, and P. W. Doetsch, “Biological consequences of oxidative stress-induced DNA damage in Saccharomyces cerevisiae,” Nucleic Acids Research, vol. 32, no. 12, pp. 3712–3723, 2004.

M. Viuda-Martos, Y. Ruiz-Navajas, J. Fernández-López, and J. A. Pérez-Álvarez, “Functional properties of honey, propolis, and royal jelly,” Journal of Food Science, vol. 73, no. 9, pp. R117–R124, 2008.

Z. Wu, Y. Zhao, and B. Zhao, “Superoxide anion, uncoupling proteins and Alzheimer’s disease,” Journal of Clinical Biochemistry and Nutrition, vol. 46, no. 3, pp. 187–194, 2010.

F. J. Pashkow, “Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention?” International Journal of Inflammation, vol. 2011, Article ID 514623, 9 pages, 2011.

R. Schnabel and S. Blankenberg, “Oxidative stress in cardiovascular disease: successful translation from bench to bedside?” Circulation, vol. 116, no. 12, pp. 1338–1340, 2007.

M. Nader, D. S. El-Agamy, and G. M. Suddek, “Protective effects of propolis and thymoquinone on development of atherosclerosis in cholesterol-fed rabbits,” Archives of Pharmacal Research, vol. 33, no. 4, pp. 637–643, 2010.

A. Scalbert, I. T. Johnson, and M. Saltmarsh, “Polyphenols: antioxidants and beyond,” The American Journal of Clinical Nutrition, vol. 81, no. 1, supplement, pp. 215S–217S, 2005.

N. Almaraz-Abarca, M. da Graça Campos, J. A. Ávila-Reyes, N. Naranjo-Jiménez, J. Herrera Corral, and L. S. González-Valdez, “Antioxidant activity of polyphenolic extract of monofloral honeybee-collected pollen from mesquite (Prosopis juliflora, Leguminosae),” Journal of Food Composition and Analysis, vol. 20, no. 2, pp. 119–124, 2007.

S. Fabris, M. Bertelle, O. Astafyeva et al., “Antioxidant properties and chemical composition relationship of Europeans and Brazilians propolis,” Pharmacology & Pharmacy, vol. 4, no. 1, pp. 46–51, 2013.

C. M. Mihai, L. A. Márghitaş, D. S. Daniel, S. Dezmiorean, and L. Bărnutiu, “Correlation between polyphenolic profile and antioxidant activity of propolis from Transylvania,” Animal Science and Biotechnologies, vol. 44, no. 2, pp. 100–103, 2011.

G. G. Duthie, P. T. Gardner, and J. A. M. Kyle, “Plant polyphenols: are they the new magic bullet?” Proceedings of the Nutrition Society, vol. 62, no. 3, pp. 599–603, 2003.

H. Yang, Y. Dong, H. Du, H. Shi, Y. Peng, and X. Li, “Antioxidant compounds from propolis collected in Anhui, China,” Molecules, vol. 16, no. 4, pp. 3444–3455, 2011.

V. Silva, G. Genta, M. N. Möller et al., “Antioxidant activity of Uruguayan propolis. In vitro and cellular assays,” Journal of Agricultural and Food Chemistry, vol. 59, no. 12, pp. 6430–6437, 2011.
[98] S. Juman, N. Yasui, K. Ikeda et al., “Caffeic acid phenethyl ester suppresses the production of pro-inflammatory cytokines in hypertrophic adipocytes through lipopolysaccharide-stimulated macrophages,” Biological and Pharmaceutical Bulletin, vol. 35, no. 11, pp. 1941–1946, 2012.

[99] J. L. Machado, A. K. Assuncao, M. C. da Silva et al., “Brazilian green propolis: anti-inflammatory property by an immunomodulatory activity,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID e0116355, 2012.

[100] F. Teles, T. M. da Silva, F. P. da Cruz Júnior et al., “Brazilian red propolis attenuates hypertension and renal damage in 5/6 renal ablation model,” PLoS ONE, vol. 10, no. 1, Article ID e0116355, 2015.

[101] M. C. Búfalo, I. Ferreira, G. Costa et al., “Propolis and its constituent caffeic acid suppress LPS-stimulated pro-inflammatory response by blocking NF-κB and MAPK activation in macrophages,” Journal of Ethnopharmacology, vol. 149, no. 1, pp. 84–92, 2013.

[102] G. Valenzuela-Barra, C. Castro, C. Figueroa et al., “Anti-inflammatory activity and phenolic profile of propolis from two locations in Región Metropolitana de Santiago, Chile,” Journal of Ethnopharmacology, vol. 168, pp. 37–44, 2015.

[103] L. H. Boudreau, J. Maillet, L. M. LeBlanc et al., “Caffeic acid phenethyl ester and its amide analogue are potent inhibitors of leukotriene biosynthesis in human polymorphonuclear leukocytes,” PLoS ONE, vol. 7, no. 2, Article ID e31833, 2012.

[104] N. Oršolić, J. Krusic, D. Crossed D Signicič, and G. Stanic, “Inhibitory effect of a propolis on Dl-n-Propyl Disulfide or n-Hexyl salicylate-induced skin irritation, oxidative stress and inflammatory responses in mice,” Fitoterapia, vol. 93, pp. 18–30, 2014.

[105] C. L. Orsatti, F. Missima, A. C. Pagliarone et al., “Propolis immunomodulatory action in vivo on toll-like receptors 2 and 4 expression and on pro-inflammatory cytokines production in mice,” Phytotherapy Research, vol. 24, no. 8, pp. H141–H146, 2010.

[106] N. Ivanovska, H. Neychev, Z. Stefanova, V. Bankova, and S. Popov, “Influence of cinnamic acid on lymphocyte proliferation, cytokine release and Klebsiella infection in mice,” Apidologie, vol. 26, no. 2, pp. 73–81, 1995.

[107] R. O. Orsi, S. R. Funari, A. M. V. C. Soares, and et al, “Immunomodulatory action of propolis on macrophage activation,” Journal of Venomous Animals and Toxins, vol. 6, no. 2, pp. 205–219, 2000.

[108] A. Sá-Nunes, L. H. Faccoli, and J. M. Sforcin, “Propolis: Lymphocyte proliferation and IFN-γ production,” Journal of Ethnopharmacology, vol. 87, no. 1, pp. 93–97, 2003.

[109] F. Missima and J. M. Sforcin, “Green Brazilian propolis action on macrophages and lymphoid organs of chronically stressed mice,” Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 1, pp. 71–75, 2008.

[110] Syamsudin, R. M. Dewi, and Kusmardi, “Immunomodulatory and in vivo antiplasmodial activities of propolis extracts,” American Journal of Pharmacology and Toxicology, vol. 4, no. 3, pp. 75–79, 2009.

[111] C. L. Orsatti and J. M. Sforcin, “Propolis immunomodulatory activity on TLR-2 and TLR-4 expression by chronically stressed mice,” Natural Product Research, vol. 26, no. 5, pp. 446–453, 2012.

[112] L.-C. Wang, Y.-L. Lin, Y.-C. Liang et al., “The effect of caffeic acid phenethyl ester on the functions of human monocyte-derived dendritic cells,” BMC Immunology, vol. 10, article 39, 2009.

[113] M. C. Búfalo, A. P. Bordon-Graciani, B. J. Conti, M. de Assis Golim, and J. M. Sforcin, “The immunomodulatory effect of propolis on receptors expression, cytokine production and fungicidal activity of human monocytes,” Journal of Pharmacy and Pharmacology, vol. 66, no. 10, pp. 1497–1504, 2014.

[114] M. C. Búfalo and J. M. Sforcin, “The modulatory effects of caffeic acid on human monocytes and its involvement in propolis action,” Journal of Pharmacy and Pharmacology, vol. 67, no. 5, pp. 740–745, 2015.

[115] F. Missima, A. C. Pagliarone, C. L. Orsatti, and J. M. Sforcin, “The effect of propolis on pro-inflammatory cytokines produced by melanoma-bearing mice submitted to chronic stress,” Journal of ApiProduct & ApiMedical Science, vol. 1, no. 1, pp. 11–15, 2009.

[116] T. F. Bachiega, C. L. Orsatti, A. C. Pagliarone, and J. M. Sforcin, “The effects of propolis and its isolated compounds on cytokine production by murine macrophages,” Phytotherapy Research, vol. 26, no. 9, pp. 1308–1313, 2012.

[117] S. S. da Silva, S. Thome Gda, A. H. Cataneo et al., “Brazilian propolis antileishmanial and immunomodulatory effects,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 673058, 7 pages, 2013.

[118] Y. Okamoto, T. Hara, T. Ebato, T. Fukui, and T. Masuzawa, “Brazilian propolis ameliorates trinitrobenzene sulfonic acid-induced colitis in mice by inhibiting Th differentiation,” International Immunopharmacology, vol. 16, no. 2, pp. 178–183, 2013.

[119] G. Gekker, S. Hu, M. Spivak, J. R. Lokensgard, and P. K. Peterson, “Anti-HIV-1 activity of propolis in CD4+ lymphocytes and microglial cell cultures,” Journal of Ethnopharmacology, vol. 102, no. 2, pp. 158–163, 2005.

[120] M. Amoros, F. Sauvager, L. Girre, and M. Cormier, “In vitro antiviral activity of propolis,” Apidologie, vol. 23, no. 3, pp. 231–240, 1992.

[121] J. Serkedjieva, N. Manolova, and V. Bankova, “Anti-influenza virus effect of some propolis constituents and their analogues (esters of substituted cinnamic acids),” Journal of Natural Products, vol. 55, no. 3, pp. 294–297, 1992.

[122] T. Shimizu, A. Hino, A. Tsutsumi, Y. K. Park, W. Watanabe, and M. Kurokawa, “Anti-influenza virus activity of propolis in vitro and its efficacy against influenza infection in mice,” Antiviral Chemistry and Chemotherapy, vol. 19, no. 1, pp. 7–13, 2008.

[123] P. Schnitzler, A. Neuner, S. Nolkeper et al., “Antiviral activity and mode of action of propolis extracts and selected compounds,” Phytotherapy Research, vol. 24, supplement 1, pp. S20–S28, 2010.

[124] G. Sartori, A. P. Pesarico, S. Pinton et al., “Protective effect of brown Brazilian propolis against acute vaginal lesions caused by herpes simplex virus type 2 in mice: involvement of antioxidant and anti-inflammatory mechanisms,” Cell Biochemistry and Function, vol. 30, no. 1, pp. 1–10, 2012.

[125] G. R. Coelho, R. Z. Mendonça, K. D. Vilar et al., “Antiviral action of hydromethanolic extract of geopropolis from Scaptotrigona postica against antiherpes simplex virus (HSV-1),” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 296086, 10 pages, 2015.

[126] S. Tait, A. L. Salvati, N. Desideri, and L. Fiore, “Antiviral activity of substituted homoisoflavonoids on enteroviruses,” Antiviral Research, vol. 72, no. 3, pp. 252–255, 2006.
Evidence-Based Complementary and Alternative Medicine

PAKI signaling and suppresses the growth of NF tumors in mice,” *Phytotherapy Research*, vol. 23, no. 3, pp. 423–427, 2009.

[157] S. Awale, F. Li, H. Onozuka, H. Esumi, Y. Tezuka, and S. Kadota, “Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANc-1 cancer cell line in nutrient-deprived condition,” *Bioorganic & Medicinal Chemistry*, vol. 16, no. 1, pp. 181–189, 2008.

[158] H. Li, A. Kapur, J. X. Yang et al., “Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin,” *International Journal of Oncology*, vol. 31, no. 3, pp. 601–606, 2007.

[159] G. Ozturk, Z. Ginis, S. Akyol, G. Erden, A. Gurel, and O. Akyol, “The anticancer mechanism of caffeic acid phenethyl ester (CAPE): review of melanomas, lung and prostate cancers,” *European Review for Medical and Pharmacological Sciences*, vol. 16, no. 15, pp. 2064–2068, 2012.

[160] Y.-J. He, B.-H. Liu, D.-B. Xiang, Z.-Y. Qiao, T. Fu, and Y.-H. He, “Inhibitory effect of caffeic acid phenethyl ester on the growth of SW480 colorectal tumor cells involves β-catenin associated signaling pathway down-regulation,” *World Journal of Gastroenterology*, vol. 12, no. 31, pp. 4981–4985, 2006.

[161] C.-P. Chuu, H.-P. Lin, M. F. Ciaccio et al., “Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks,” *Cancer Prevention Research*, vol. 5, no. 5, pp. 788–797, 2012.

[162] J. Wu, C. Omene, J. Karkoszka et al., “Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer,” *Cancer Letters*, vol. 308, no. 1, pp. 43–53, 2011.

[163] C. Omene, M. Kalac, J. Wu, E. Marchi, K. Frenkel, and O. A. O’Connor, “Propolis and its active component, caffeic acid phenethyl ester (CAPE), modulate breast cancer therapeutic targets via an epigenetically mediated mechanism of action,” *Journal of Cancer Science and Therapy*, vol. 5, no. 10, pp. 334–342, 2013.

[164] C. O. Omene, J. Wu, and K. Frenkel, “Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells,” *Investigational New Drugs*, vol. 30, no. 4, pp. 1279–1288, 2012.

[165] A. M. Alizadeh, H. Afrouzan, N. Dinparast-Djadid et al., “Chemoprotection of MNNG-initiated gastric cancer in rats using Iranian propolis,” *Archives of Pharmacal Research*, vol. 25, no. 4, pp. 500–504, 2002.

[166] H. Izuta, M. Shimazawa, K. Tsuruma, Y. Araki, S. Mishima, and H. Hara, “Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells,” *BMC Complementary and Alternative Medicine*, vol. 9, article 45, 2009.

[167] V. A. Isidorov, L. Szczepaniak, and S. Bakier, “Rapid GC/MS determination of botanical precursors of eurasian propolis,” *Food Chemistry*, vol. 142, pp. 101–106, 2014.

[168] S. D. Leonhardt, H. M. Wallace, and T. Schmitt, “The cuticular profiles of Australian stingless bees are shaped by resin of the eucalypt tree Corymbia torelliana,” *Austral Ecology*, vol. 36, no. 5, pp. 537–543, 2011.

[169] R. Christov, V. Bankova, I. Tsvetkova, A. Kujumgiev, and A. Delgado Tejera, “Antibacterial furufuran lignans from Canary Islands propolis,” *Fitoterapia*, vol. 70, no. 1, pp. 89–92, 1999.

[170] J. F. Campos, U. P. dos Santos, L. F. B. Macorini et al., “Antimicrobial, antioxidant and cytotoxic activities of propolis from Melipona orbignyi (Hymenoptera, Apidae),” *Food and Chemical Toxicology*, vol. 65, pp. 374–380, 2014.
Immunomodulatory effects of Turkish propolis: changes in neopterin release of human monocytes, "Evidence-based Complementary and Alternative Medicine, vol. 19, no. 1, pp. 90–95, 2016.

R. O. Orsi, J. M. Sforcin, S. R. Cunha Funari, A. Fernandes Jr., and V. Bankova, “Synergistic effect of propolis and antibiotics on the Salmonella typhi,” Brazilian Journal of Microbiology, vol. 37, no. 2, pp. 108–112, 2006.

D. Kelleher, “Caffeic acid phenethyl ester modulates stress,” Journal of Ethnopharmacology, vol. 214, no. 2, pp. 485–491, 2017.

A. R. Khosravi, H. Shokri, D. Nikaein et al., “Yeasts as important agents of onychomycosis: in vitro activity of propolis against yeasts isolated from patients with nail infection,” Journal of Alternative and Complementary Medicine, vol. 19, no. 1, pp. 57–62, 2013.

H. C. Kuo, W. H. Kuo, Y. J. Lee, W. L. Lin, F. P. Chou, and T. H. Tseng, “Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo," Cancer Letters, vol. 234, no. 2, pp. 199–208, 2006.

Y.-J. Chen, M.-S. Shiao, M.-L. Hsu, T.-H. Tsai, and S.-Y. Wang, “Effect of caffeic acid phenethyl ester, an antioxidant from propolis, on inducing apoptosis in human leukemic HL-60 cells,” Journal of Agricultural and Food Chemistry, vol. 49, no. 11, pp. 5615–5619, 2001.

Y. Akao, H. Maruyama, K. Matsumoto et al., “Cell growth inhibitory effect of cinnamic acid derivatives from propolis on human tumor cell lines,” Biological and Pharmaceutical Bulletin, vol. 26, no. 7, pp. 1057–1059, 2003.

H. Hattori, K. Okuda, T. Murase et al., “Isolation, identification, and biological evaluation of HIF-1-modulating compounds from Brazilian green propolis,” Bioorganic and Medicinal Chemistry, vol. 19, no. 18, pp. 5392–5401, 2011.

C. A. Dornelas, F. V. Fechine-Jamacaru, I. L. Albuquerque et al., “Angiogenesis inhibition by green propolis and the angiogenic effect of L-lysine on bladder cancer in rats,” Acta Cirurgica Brasileira, vol. 27, no. 8, pp. 529–536, 2012.

J. B. Daleprane, T. Schmid, N. Dehne et al., “Suppression of hypoxia-inducible factor-α contributes to the antiangiogenic activity of red propolis polyphenols in human endothelial cells,” Journal of Nutrition, vol. 142, no. 3, pp. 441–447, 2012.

T. Kamiya, H. Nishiha, H. Harad, and T. Adachi, “Ethanol extract of Brazilian red propolis induces apoptosis in human breast cancer MCF-7 cells through endoplasmic reticulum
Evidence-Based Complementary and Alternative Medicine

stress,” *Journal of Agricultural and Food Chemistry*, vol. 60, no. 44, pp. 11065–11070, 2012.

[213] H.-P. Lin, S. S. Jiang, and C.-P. Chuu, “Caffeic acid phenethyl ester causes p21cip1 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells,” *PLoS ONE*, vol. 7, no. 2. Article ID e31286, 2012.

[214] Y.-Y. Kuo, H.-P. Lin, C. Huo et al., “Caffeic acid phenethyl ester suppresses proliferation and survival of TW2.6 human oral cancer cells via inhibition of akt signaling,” *International Journal of Molecular Sciences*, vol. 14, no. 5, pp. 8801–8817, 2013.

[215] H. J. Hwang, H. J. Park, H.-J. Chung et al., “Inhibitory effects of caffeic acid phenethyl ester on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells,” *Journal of Nutritional Biochemistry*, vol. 17, no. 5, pp. 356–362, 2006.

[216] H. Seda Vatansever, K. Sorkun, S. Ismet Deliloğlu Gurhan et al., “Propolis from Turkey induces apoptosis through activating caspases in human breast carcinoma cell lines,” *Acta Histochemica*, vol. 112, no. 6, pp. 546–556, 2010.

[217] M. Watabe, K. Hishikawa, A. Takayanagi, N. Shimizu, and T. Nakaki, “Caffeic acid phenethyl ester induces apoptosis by inhibition of NFkappaB and activation of Fas in human breast cancer MCF-7 cells,” *The Journal of Biological Chemistry*, vol. 279, no. 7, pp. 6017–6026, 2004.

[218] I. Valença, F. Morais-Santos, V. Miranda-Gonçalves, A. M. Ferreira, C. Almeida-Aguiar, and F. Baltazar, “Portuguese propolis disturbs glycolytic metabolism of human colorectal cancer in vitro,” *BMC Complementary and Alternative Medicine*, vol. 13, article 184, 2013.